Innate Pharma 20F/A 2022 Annual report (foreign) (amended) | IPHA Filing

Exhibit 4.9

Execution Version

RESEARCH COLLABORATION & LICENSE AGREEMENT

INNATE PHARMA

and

GENZYME CORPORATION

1/147

TABLE OF CONTENTS


ARTICLE 1. DEFINITIONS & INTERPRETATION		5
1.1	Definitions	5
1.2	Interpretation	18
ARTICLE 2. RESEARCH COLLABORATION AND LICENSE GRANTS		18
2.1	Research Collaboration	18
2.2	License Grants	19
ARTICLE 3. TECHNOLOGY AND MATERIALS TRANSFER		23
3.1	Technology and Materials Transfer	23
3.2	Assistance	24
ARTICLE 4. RESEARCH COLLABORATION		24
4.1	Research Program(s) and Sanofi Option	24
4.2	New Target Selection Process	25
4.3	Work Plan	25
4.4	Research Program Period	26
4.5	Nomination Process for Pre-Hits, Hits, Leads, Pre-Development Candidates, Candidates and Back-Ups	26
4.6	Performance Generally	27
4.7	Records	27
4.8	Progress Reports and Forecasts	27
4.9	Audit rights	27
4.10	Animal Welfare	28
4.11	Performance by Affiliates	28
4.12	Subcontracting	28
ARTICLE 5. GOVERNANCE OF THE COLLABORATION		28
5.1	Joint Scientific Committee	28
5.2	Joint Project Team	31
5.3	Program Managers	32
5.4	Alliance Managers	32
ARTICLE 6. DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION		33
6.1	Overall Responsibility	33
6.2	Development	33
6.3	Regulatory Approvals	33
6.4	Manufacturing	34
6.5	Commercialization	34
6.6	Diligence	34
6.7	Reporting	34
ARTICLE 7. FINANCIAL PROVISIONS		34
7.1	Research Program Costs	34
7.2	Development, Manufacturing and Commercialization Costs	34
7.3	Upfront Payment	34
7.4	Option Fee	35
7.5	Milestones Payments	35
7.6	Royalties	38
7.7	Payments by Innate to Sanofi upon the exercise by Innate of its Reversion Rights	42
7.8	Taxes and Withholding	42
7.9	Payment Terms	43
ARTICLE 8. INTELLECTUAL PROPERTY RIGHTS		44
8.1	Intellectual Property Ownership	44
8.2	Filing, Prosecution and Maintenance of Patent Rights	46
8.3	Enforcement of Patent Rights	50
8.4	Third Party Infringement Defense	52
8.5	Invalidity or Unenforceability Defense	53
8.6	Third Party Post Grant Proceedings	53
8.7	CREATE Act	54

2/147


ARTICLE 9. REPRESENTATIONS AND WARRANTIES - CLOSING CONDITIONS		54
9.1	Mutual Representations and Warranties	54
9.2	Representations and Warranties of Innate	55
9.3	Representations and Warranties of Sanofi	56
9.4	DISCLAIMER	56
9.5	Closing Conditions.	57
ARTICLE 10. NONDISCLOSURE OF CONFIDENTIAL INFORMATION		57
10.1	Nondisclosure	57
10.2	Exceptions	57
10.3	Authorized Disclosure	58
10.4	Securities Filings	59
10.5	Relationship to Confidentiality Agreement	59
10.6	Publication	60
ARTICLE 11. INDEMNIFICATION		61
11.1	Indemnification by Sanofi	61
11.2	Indemnification by Innate	61
11.3	Indemnification Procedure	62
11.4	Indemnification Payment Adjustments	63
ARTICLE 12. TERM AND TERMINATION		63
12.1	Effectiveness; Term	63
12.2	Termination Rights	63
12.3	Consequences of Termination	64
ARTICLE 13. GOVERNMENT APPROVALS		71
13.1	Efforts.	71
13.2	Filings.	72
13.3	Information Exchange.	72
ARTICLE 14. MISCELLANEOUS		73
14.1	Severability	73
14.2	Notices	73
14.3	Force Majeure	74
14.4	Assignment	74
14.5	Further Assurances	74
14.6	Waivers and Modifications	74
14.7	Choice of Law	74
14.8	Jurisdiction	75
14.9	Publicity	75
14.10	Relationship of the Parties	75
14.11	Entire Agreement	75
14.12	Counterparts	75
14.13	Amendments	75
14.14	No presumption against the drafters	75
Schedule 3.1.1(a)
Schedule 3.1.1(b)
Schedule 4.1
Schedule 4.3
Schedule 4.10
Schedule 7.7
Schedle 14.9

3/147

THIS RESEARCH COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made this 16th day of December 2022 (the “Execution Date”)

BY AND BETWEEN:

1. Innate Pharma S.A., a French corporation having offices at 117, avenue de Luminy BP 30191 - 13276 Marseille cedex 09, France; hereinafter referred to as “Innate”; and

2. Genzyme Corporation, a corporation existing under the laws of Massachusetts, USA with a business address at 450 Water Street, Cambridge, Massachusetts 02141, USA; hereinafter referred to as “Sanofi” and a wholly owned subsidiary of Sanofi, a French corporation;

Innate and Sanofi are hereinafter individually referred to as a “Party” and together as the “ Parties”.

WHEREAS:

A. Sanofi is a leading pharmaceutical company, committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human medicine notably in the field of cancer treatment and immunological & inflammatory diseases; and

B. Innate is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases which possesses certain expertise and owns or controls certain intellectual property rights related to Antibodies targeting the NKp46 antigen and a Multispecific Antibody format for the potential treatment in humans of various types of cancer, ANKET™ (Antibody-based NK cell Engager Therapeutics); and

C. Innate has researched, discovered and developed Natural Killer Cell Engager products (“NKCE” as defined below) targeting the NKp46 antigen, ANKET™, including B7-H3 ANKET4 that selectively binds to at least NKp46 and B7H3 (the “First Product”).

D. Sanofi and Innate wish to collaborate in the testing and evaluation of NKCEs targeting B7H3, including the First Product, and up to two other NKCEs targeting different antigens at the surface of tumor cells; and

E. Innate desires to grant to Sanofi, and Sanofi desires to obtain from Innate, exclusive rights to, and associated intellectual property in the Innate IP and the Collaboration IP (as defined below) to research, develop, manufacture and commercialize NKCEs, subject to the terms and conditions described below; and

F. Upon completion of the Research Program, Sanofi shall be responsible for the preclinical and clinical development, manufacture and commercialization of Candidates and Products (as defined below); and

G. Sanofi and Innate therefore wish to enter into this Agreement relating to the research, development, manufacture and commercialization of Candidates and Products, all in accordance with the terms and conditions set out in this Agreement.

Unless otherwise defined in the Agreement, capitalized terms used in this Agreement, including in paragraphs A to G, shall have the meaning given to such terms in Article 1.

4/147

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree as follows:

ARTICLE 1. DEFINITIONS & INTERPRETATION

1.1 Definitions

In this Agreement the following definitions shall have the following meanings unless otherwise expressly provided or unless the context otherwise requires:

“Accounting Standard” means, with respect to a Party or its Affiliate or Sublicensee, GAAP or IFRS, as such Party, Affiliate or Sublicensee uses for its financial reporting obligations, in each case consistently applied across its operations.

“Act” means the US Federal Food, Drug, and Cosmetic Act.

“Activating Receptor” means NKp46, NKp30 and any other receptor expressed at the surface of NK cells which when crosslinked on the NK cells in isolation, causes increased cytotoxicity or cytokine secretion by the NK cells.

“Affiliate” means with respect to a Party, any Person that (directly or indirectly) is controlled by, controls, or is under common control with such Party controlling, controlled by, or under common control with, such Party where control means the direct or indirect ownership of voting securities entitled to cast more than fifty percent (50%) of the votes in the election of directors, or such other relationship as results in actual control over the management, business, assets and affairs of an entity.

“Annual Net Sales” means, with respect to any Product, the Net Sales of such Product in any calendar year during the Term.

“Antibody” means any monoclonal or polyclonal antibody, whether multiple or single chain, recombinant or naturally occurring, whole or fragment, and any variants, derivatives or constructs thereof, including but not limited to, nanobodies, antigen binding portions including Fab, Fab’, F(ab’)2, Fv, dAb and CDR fragments, single chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides (including any humanized versions thereof) that contain at least a portion of an immunoglobulin that is sufficient to bind selectively to a specific antigen.

“Antibody Format” means the number of polypeptides and the polypeptides pairing and arrangement used to generate a given format of a Multispecific Antibody, together with the arrangement of the building blocks included in each of said polypeptides (e.g. Fab, Fv, ScFv, variable domains VH and VL, Fc region, peptide linkers, cytokine moiety, or fragment thereof).

“Antigen Binding Domain” means a three-dimensional structure capable of immunospecifically binding to an epitope and comprising at least a complementarity-determining region (CDR), optionally a VH and/or VL domain, of an antibody chain.

“Antitrust Law” means any Applicable Law that is designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization, lessening of competition or restraint of trade, including the HSR Act, the Sherman Act, the Clayton Act, and the Federal Trade Commission Act, each as amended.

5/147

“Applicable Laws” means all laws, rules and regulations (including any rules, regulations, guidelines or other requirements of national and international patent offices and of the Regulatory Authorities) that may be in effect from time to time in the Territory that apply to either (i) the Research Program activities; (ii) the research, Development or other Exploitation of the Products in the Territory; or (iii) the performance of either Party’s obligations under this Agreement.

“Business Day” means 9.00 am to 5.00 pm local time on a day other than a Saturday, Sunday or any other day on which commercial banks in France and/or in the US are authorised or required by law to close.

“ Back-Up” means a Multispecific Antibody selected among the Hits, Leads, and Pre-Development Candidates, other than the Candidate, and nominated as such by the JSC.

“Candidates” means any Multispecific Antibody nominated as such by the JSC in accordance with the timeline and criteria set forth in the Work Plan or otherwise nominated by Sanofi under Section 4.5.5.

“ CDR” means complementarity determining region.

“CMC” means “Chemistry, Manufacturing and Controls” as such term of art is used in the pharmaceutical industry.

“CMC Activities” means the CMC and manufacturing process development activities conducted by or on behalf of the Parties (or their Affiliates), solely or jointly, under the Research Program(s) during the Research Program Period.

“CMC Materials” means any and all Materials conceived, discovered, generated, developed or otherwise made or acquired solely or jointly by or on behalf of the Parties during the Research Program Period and that directly arise from the conduct by the Parties of the CMC Activities under the Research Program(s).

“CMC Technology” means the Know-How made, conceived, discovered, generated, developed, or otherwise made or acquired, solely or jointly, or first reduced to practice by or on behalf of either Party (or its Affiliates), or jointly by or on behalf of the Parties (or their Affiliates), in the conduct of CMC Activities.

“ Collaboration IP” means the Collaboration Technology, the Collaboration Patents and all other Intellectual Property Rights in or to the Collaboration Technology or Collaboration Materials.

“Collaboration Materials” means any and all Multispecific Antibodies or other Materials conceived, discovered, generated, developed or otherwise made or acquired solely or jointly by or on behalf of the Parties during the Research Program Period and that directly arise from the conduct by the Parties of their activities under the Research Program(s), as updated from time to time, excluding Sanofi Materials, Innate Materials and any Materials arising outside of the conduct by the Parties of their activities under the Research Program(s).

“Collaboration Patents” means any and all Patent Rights that claim an invention within the Collaboration Technology or Collaboration Materials, provided such Collaboration Technology and Collaboration Materials were invented, conceived or reduced to practice during the Research Program Period.

“Collaboration Technology” means all Know-How conceived, discovered, generated, developed or otherwise made or acquired, solely or jointly, by or on behalf of the Parties in the conduct of their activities, under the Research Program(s) during the Research Program Period excluding Sanofi

6/147

Technology, Innate Technology and any Know-How arising outside of the conduct by the Parties of their activities pursuant to the Research Program(s).

“Commercial Sale” means, with respect to a Product, an arm’s length sale for monetary value by Sanofi, its Affiliates, or Sublicensees to a Third Party for end use or consumption by the general public in a country where Marketing Authorization of such Product has been obtained by Sanofi, its Affiliates, or Sublicensees; provided, however, that in no event shall any sale or distribution of a Product for pre-Marketing Authorization activities or use in a clinical trial or otherwise any sales prior to receipt of all Regulatory Approvals necessary to commence regular commercial sales (including so-called “treatment IND sales” and “compassionate use sales”) be deemed a Commercial Sale.

“Commercially Reasonable Efforts” means |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||.||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||.|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||,

“Commercialization” means any and all activities directed to the preparation for sale of, offering for sale of, or sale of a product, including activities related to marketing, promoting, distributing, exporting and importing such product, and interacting with Regulatory Authorities regarding any of the foregoing. When used as a verb, “to Commercialize” and “Commercializing” means to engage in Commercialization, and “Commercialized” has a corresponding meaning.

“Confidential Information” means the following: (i) the terms and conditions of this Agreement, for which each Party will be considered a Disclosing Party and a Receiving Party; (ii) Innate Technology, Innate Materials, for which Innate will be considered the Disclosing Party and Sanofi will be considered the Receiving Party; (iii) Sanofi Technology, Sanofi Materials, for which Sanofi will be considered the Disclosing Party and Innate will be considered the Receiving Party; (iv) Collaboration Technology and Collaboration Materials will be considered Confidential Information of both Parties, and (v) any other Know-How or Materials, whether or not patentable, or disclosed or provided by one Party to the other Party in connection with this Agreement, whether before, on or after the Execution Date, including information regarding such Party’s strategy, business plans, objectives, research, technology, products, business affairs or finances including any non-public data relating to the Development or Exploitation of any Candidate or Product and other Know-How or Materials of the type that is customarily considered to be confidential information by parties engaged in activities that are substantially similar to the activities being engaged in by the Parties under this Agreement, for which the Party making such disclosure will be considered the Disclosing Party and the receiver will be the Receiving Party.

“Contemplated Transactions” means the transactions contemplated by this Agreement.

“Control” means, with respect to any Patent Right, Know-How, Material, Trade Mark or other Intellectual Property Right, the right owned by a Party or its Affiliates, whether directly or indirectly, to grant the licenses or sublicenses granted hereunder, whether by ownership, license (other than pursuant to this Agreement) or otherwise without violating the terms of any agreement with any Third Party or any other arrangement with any Third Party and with respect to any Intellectual Property Rights that become controlled after the Effective Date pursuant to the preceding sentence, without having to make any payment to such Third Party. Notwithstanding the foregoing, a Party will be deemed not to “Control” any intellectual property rights or rights of reference that are owned or in-licensed by a Third Party (or any Affiliates of such Third Party in existence prior to the Change of Control, other than such Party or its Affiliates) that becomes an Affiliate of such Party (or that merges or consolidates with such Party) after the Effective Date as a result of a Change of Control of such Party. For purposes of the foregoing “Change of Control” means that a Third Party acting alone or with others gains the control

7/147

(as such term is defined in the definition of Affiliates) of a Party through an acquisition, investment or otherwise.

“Development” and, with correlative meaning, “Develop”, means all post-Research Program Period but pre-Regulatory Approval activities regarding a Candidate, or Product in a country of the Territory conducted with the aim of obtaining such Regulatory Approval including: (i) studies on the toxicological, pharmacological, metabolic or clinical aspects of a Product conducted internally or by individual investigators or consultants; (ii) process development, process improvement, scale-up and recovery, the manufacture of clinical supplies of Product, including failed batches, and manufacture of qualification lots; and (iii) preparing, submitting, reviewing or developing data or information for the purpose of submission to a Regulatory Authority to obtain, maintain or expand manufacturing or Regulatory Approval of a Product, including data management, statistical designs and studies, document preparation, and other administration.

“Disclosing Party” means the Party which discloses Confidential Information to the other Party.

“Discontinued Product” has the meaning given to it in Section 12.3.1.

“Effective Date” is defined in Section 13.2 (Filings).

“EMA” means the European Medicines Agency and any successor agency thereto.

“European Patent” means patents granted through, and patent applications filed with, the European Patent Office under the European Patent Convention.

“European Union” or “EU” means the countries of the European Union as constituted from time to time during the Term.

“Execution Date” means the date referred to on the first page of this Agreement.

“Exploit” means to make, have made, import, use, sell, or offer for sale, including to research, have researched, develop, have developed, register, modify, enhance, improve, manufacture, have manufactured, hold/keep (whether for disposal or otherwise), formulate, optimise, have used, export, transport, distribute, promote, market or have sold or otherwise dispose or offer to dispose of, a product or process and “Exploitation” means the act of Exploiting a product or process.

“FDA” means the United States Food and Drug Administration and any successor agency thereto.

“Field” means all therapeutic, prophylactic and diagnostic indications for human or veterinary use.

“First Commercial Sale” means the first Commercial Sale by or on behalf of Sanofi, its Affiliates or Sublicensees of a Product.

“FTE” means the equivalent of the work of a full-time individual for a twelve (12) month period.

“GAAP” means the US generally accepted accounting principles.

“Generic Product” means, with respect to a given Product in a given country of the Territory, any biological product that (i) is sold by a Third Party that is not a Sublicensee or Affiliate of Sanofi and without the consent of Sanofi, under a Regulatory Approval granted by a Regulatory Authority to such Third Party; (ii) is similar to such Product, notwithstanding minor differences in clinically inactive components; and (iii) is approved in reliance, in whole or in part, on (A) a prior Regulatory Approval (or on any safety or efficacy data submitted in support of a prior Regulatory Approval) of such Product or reference to other publicly available clinical data with respect to such Product, or (B) a demonstration

8/147

of bioequivalence to or interchangeability with such Product. Without limiting the foregoing, a “biosimilar,” “follow-on biologic,” or “biosimilar biologic product” with respect to a Product in a given country that meets the criteria set forth in (i), (ii) and (iii) constitutes a “Generic Product” with respect to such Product in such country.

“GCP” means Good Clinical Practices as set forth in, as applicable, the ICH Harmonized Guidance on Good Clinical Practice (CPMP/ICH/135/95), 21 C.F.R. Parts 50 and 56 et seq., and other equivalent regulations or standards in the Territory, including as such standards, practices, procedures, requirements and regulations may be amended from time to time.

“GLP” means Good Laboratory Practices as set forth in 21 C.F.R. Part 58, et seq., the Directive 2004/9/EC and 2004/10/EC of the European Parliament and of the Council, and other equivalent regulations or standards in the Territory, including as such standards, practices, procedures, requirements and regulations may be amended from time to time.

“GMP” means Good Manufacturing Practices as set forth in, as applicable, 21 C.F.R. Part 210, et seq., the Rules Governing Medicinal Products in the European Union volume 4, and other equivalent regulations or standards in the Territory, including as such standards, practices, procedures, requirements and regulations may be amended from time to time.

“GLP-Tox Study” means an in-vivo GLP preclinical research study of the toxicological effects (and, in some case, pharmacokinetic properties) of a Candidate.

“Healthcare Company” means any independent Third Party entity that conducts research, development, and/or commercialization of pharmaceutical products in the biotechnology or pharmaceutical industry or develops or commercializes therapeutic or diagnostic products.

“Hits” means any Multispecific Antibody nominated as such by the Project Leaders in accordance with the timeline and criteria set forth in the Work Plan.

“HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (15 U.S.C. § 18a) and the rules and regulations promulgated thereunder.

“HSR/Antitrust Filing” is defined in Section 13.2.

“IFRS” means the International Financial Reporting Standards.

“IND” means an investigational new drug application filed with the FDA for authorisation to commence clinical trials in humans, or its equivalent in other countries or regulatory jurisdictions.

“Indication” means a specific disease or medical condition in humans that is approved by a Regulatory Authority to be included as a discrete claim (as opposed to a variant or subdivision or subset of a claim) in the labelling of a Product; provided, however, with respect to oncology Indications, a particular oncology Indication will be considered distinct from another oncology Indication only if it (a) has a different organ of origin for solid tumors (e.g., lung, breast, liver) or if it is for a different hematological malignancy, and (b) has (i) an annual incidence of no less than 10 000 patients in the aggregate in the Major Markets Countries or (ii) prevalence of no less than 10 000 patients in the aggregate in the Major Market Countries if the median overall survival rate is greater than one year, in both case (i) and (ii), according to the statistics from the Surveillance, Epidemiology, and End Results Program (SEER) (https://seer.cancer.gov/) or similar data in the Major Market Countries. For clarity, the following shall be part of the same Indication: (a) different lines of therapy (e.g., first line and second line treatments, etc.); (b) different stages of disease (e.g., localized vs. metastatic cancer, etc.); (c) biomarker status with respect to a disease (e.g., PD-L1 positive / negative, ALK positive / negative, etc.); (d) variants or subdivisions or subclassifications of such Indication; (e) treatment, modulation and prophylaxis of a

9/147

disease or medical condition or (f) treatment as monotherapy and treatment in combination with another product.

“Innate Antibody” means Innate’s proprietary Antibodies targeting the NKp46 antigen, or other Antibodies proposed by Innate during the Research Program Period and agreed by mutual agreement through the JSC. as described in Schedule 3.1.1(a).

|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

“Innate Format” means certain Innate’s proprietary Antibody Format, as well as any cytokine moiety for use therein, as described in Schedule 3.1.1(a) as updated during the Research Program Period by mutual agreement through the JSC, including any specific and Non-Severable Modification or Improvement thereof conceived, discovered, generated, developed or otherwise made or acquired by either Party in the conduct of the activities pursuant to the Research Program during the Research Program Period.

“Innate Indemnified Parties” has the meaning given to it in Section 11.1.

“Innate IP” means the Innate Technology, the Innate Patents and all other Innate Intellectual Property Rights in or to the Innate Technology or Innate Materials.

“Innate Materials” means with respect to any Research Program (i) any and all Multispecific Antibody or other Materials Controlled by Innate at the Execution Date as listed in Schedule 3.1.1(a) as updated during the Research Program Period by mutual agreement through the JSC, (ii) any and all materials conceived, discovered, generated, developed or otherwise made or acquired by or on behalf of Innate outside of the conduct of its activities pursuant to the Research Program dining the Research Program Period and contributed by Innate for use in the Research Program, (iii) Innate CMC Materials, and (iv) any and all Materials, conceived, discovered, generated, developed or otherwise made or acquired in the conduct of the activities pursuant to the Research Program which are solely related to the Innate Technology and/or the Innate Format and/or the Innate Antibodies.

“Innate Patents” means any and all Patent Rights Controlled by Innate or its Affiliates that claim an invention within the Innate Technology as listed in Schedule 3.1.1(a) hereto, as updated from time to time.

“Innate Technology” means, with respect to any Research Program, (i) all Know-How (other than Materials) that is related to the First Product, the Innate Antibody and the Innate Format and is Controlled by Innate at the Effective Date, (ii) all Know-How that is related to the Multispecific Antibody targeting a Selected Target brought by Innate to the collaboration through the Option Data Package and is Controlled by Innate at the time of the Option exercise with respect to that Selected Target, (iii) the Innate CMC Technology, and (iv) all Know-How to the extent relating solely to the Innate Format and/or the Innate Antibodies and/or other Innate Materials and conceived, discovered, generated, developed or otherwise made, or acquired in the conduct of the Research Program(s).

10/147

“Intellectual Property Rights” means Patent Rights, rights to inventions or Know-How, copyright, Trade Marks, domain names, rights in trade dress or get-up, rights in goodwill or to sue for passing off, unfair competition rights, rights in designs, rights in computer software, database rights, topography rights (all whether capable of being patented or registered or not), moral rights, rights in confidential information and any other intellectual property rights, in each case whether registered or unregistered and including all registrations of, applications for registration of and renewals of such rights, and all similar or equivalent rights or forms of protection in any part of the world.

“Joint Steering Committee” or “JSC” means the committee comprising Sanofi representatives and Innate representatives to be established by the Parties pursuant to Article 5.

“Jointly Prosecuted Patents” has the meaning given to it in Section 8.2.3.

“Know-How” means any and all non -public technical, scientific and other know-how and information, inventions, trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, chemical structures and associated data, designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material (whether or not patentable) in written, electronic or any other form (including as embodied in materials) now known or later developed. For the purpose of this definition, none of the information described above shall be deemed to be in the public domain or public knowledge and therefore not constituting Know-How, merely because such information is embraced by more general information in the public domain or public knowledge. Further, any combination of individual elements of information shall not be considered known to the public merely because one or more individual elements of such combination are known to the public. For purposes of the foregoing, an information that became public as a result of a breach of confidentiality by the Receiving Party shall be deemed non-public.

“Leads” means all Multispecific Antibodies nominated as such by the JSC in accordance with the timeline and criteria set forth in the Work Plan.

“Major Market Countries” means |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||.

“Manufacture” or “Manufacturing” means all activities related to the production, manufacture, processing, formulation, filling, finishing, packaging, labelling, shipping, and holding of a Product or an intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical, and commercial manufacture and analytic development, process improvements and optimization, product characterization, stability testing, quality assurance and quality control.

“Marketing Authorisation” means, with respect to a Product, any Regulatory Approval necessary to market such Product in any country (excluding any pricing and reimbursement approvals required to effectively sell such Product in such country).

“Materials” means any chemical or biological substances including any: (i) organic or inorganic chemical or compound; (ii) gene; (iii) nucleic acid, vector or construct, whether plasmid, phage, virus or any other type; (iv) host organism, including bacteria and eukaryotic cells; (v) eukaryotic or prokaryotic cells, cell line or expression system; (vi) protein, including any peptide or amino acid sequence, enzyme, antibody or protein conferring targeting properties and any fragment of a protein or peptide or enzyme; (vii) genetic material, including any genetic control element (e.g., promoters); (viii) virus; (ix) assay or reagent or (x) genetically engineered animal models. For clarity, the term “Materials” shall include any blood sample or blood plasma sample.

“Multispecific Antibody” or “NKCE” means an Antibody with at least a first and a second Antigen Binding Domain (ABD), where the first ABD binds an Activating Receptor and the second ABD binds

11/147

a Selected Target, and whose primary action is to activate NK cell effector functions (cell cytotoxicity) by engaging, via the respective ABDs, both the Activating Receptor and the Selected Target.

“Net Sales” means, with respect to a Product, for any period, the gross amount invoiced by Sanofi or its Affiliates or Sublicensees for the sale of such Product to Third Parties, commencing with the First Commercial Sale of such Product upon meeting the applicable Accounting Standards revenue recognition criteria, less the following amounts, determined in accordance with the applicable Accounting Standards, which are actually incurred, allowed, accrued or specifically allocated, with respect to such Product over such period:

(a) discounts, including cash, trade and quantity discounts inclusive of free goods, price reduction programs (including co-pay assistance, compulsory refunds, and any other patient payment assistance programs), retroactive price adjustments with respect to sales of such Product, charge-back payments and rebates granted to managed health care organizations or to federal, state and local governments (or their respective agencies, purchasers and reimbursors) or to trade customers, including wholesalers and chain and pharmacy buying groups;

(b) amounts repaid or credited by reason of defects, damaged products, expired dating, rejections, product recalls, refunds, returns, rebates and billing errors;

(d) customs, taxes, duties or other governmental charges incurred in connection with, levied on, absorbed or otherwise imposed on sale, exportation or importation of such Product, including value-added taxes, or other governmental charges otherwise measured by the billing amount, when included in billing, as adjusted for rebates and refunds, but specifically excluding taxes based on net income of the seller;

(e) that portion of the annual fee on prescription drug manufacturers imposed by the Patient Protection and Affordable Care Act, Pub. L. No. 111-148 or its successor that Sanofi or its Affiliates or Sublicensees allocate(s) to sale of such Product, in accordance with Sanofi’s standard policies and procedures consistently applied across its products, and other similar fees and taxes, including that certain tax known with respect to pharmaceutical companies in France (remise conventionnelle);

(f) rebates, credits, compulsory refunds and similar payments made with respect to sales paid for by any Regulatory Authority including Federal or state Medicaid, Medicare or similar state program or equivalent foreign governmental program;

(g) commissions paid to Third Party distributors, brokers or agents other than sales personnel, sales representatives or sales agents employed by Sanofi or its Affiliates or Sublicensees;

(h) the portion of administrative fees paid during the relevant time period to group purchasing organizations or pharmaceutical benefit managers relating to such Product;

(i) any other invoiced amounts that are not collected and are written off by Sanofi or its Affiliates or Sublicensees in accordance with the applicable Accounting Standards, provided, however, that any such amounts subsequently collected will be included in Net Sales; and

(j) any other similar and customary deductions that are consistent with the applicable Accounting Standards as determined from the books and records of Sanofi or its Affiliates or Sublicensees, as the case may be, maintained in accordance with Sanofi’s or its Affiliates’ or Sublicensees’ normal practices.

12/147

Net Sales shall not include: (i) the sale, transfer or other disposition of a Product (x) prior to Regulatory Approval for use in clinical trials, (y) free of charge for use in special access programs or for compassionate use, or (z) free of charge of reasonable quantities of promotional samples; or (ii) the transfer of Products to an Affiliate or Sublicensee, provided that, (x) unless subject to an exception in the foregoing provison (i), the First Commercial Sale occurs if the Affiliate or Sublicensee is the end user and provided further that (y) Sanofi does not consolidate the revenues recognized by the Affiliate or Sublicensee with respect to any further resale of the Product.

In the event that a Product is sold in any country in the form of a pharmaceutical preparation in final form containing a Candidate in combination with one or more active ingredients, for sale by prescription, over-the-counter or any other method either as a fixed dose or unit or as separate doses or units in a single package (a “Combination Product”), Net Sales of such Combination Product will be adjusted by multiplying actual Net Sales of such Combination Product in such country calculated pursuant to the foregoing definition of “Net Sales” by the fraction A/(A+B), where A is the average net invoice price for the same Calendar Quarter in such country of any Product that contains the same Candidate as such Combination Product as its sole active ingredient(s), if sold separately in such country, and B is the sum of the average net invoice prices for the same Calendar Quarter in such country of the other active ingredients (the “Other Items”) in such Combination Product. If either the Product that contains the Candidate as its sole active ingredient, on the one hand, or the Other Items

(individually or collectively) are not sold separately in a particular country in the same Calendar Quarter, the Parties will negotiate in good faith a commercially reasonable adjustment to Net Sales in such country that takes into account the medical contribution to the Combination Product of, and all other factors reasonably relevant to the relative value of, the Candidate, on the one hand, and the Other Items, collectively, on the other hand.

Subject to the above, Net Sales will be calculated in accordance with the standard internal policies and procedures of Sanofi, its Affiliates or Sublicensees, which will be in accordance with the applicable Accounting Standards.

“New Target” has the meaning given to it in Section 4.1.

“Nomination Data Package” has the meaning given to it in Section 4.5.

“Non-Severable Modification or Improvement” means, with respect to a Party’s Antibody Format, a modification or an improvement of such Antibody Format that could not be Exploited without infringing a claim of Patent Rights of such Party, including any pending application if such claim were granted.

“Outside Date” means that date that is one-hundred and twenty (120) days after the date upon which an HSR/Antitrust Filing has been submitted by each Party to a Governmental Authority in relation to the Agreement.

“Party” means either Sanofi or Innate and “Parties” means Sanofi and Innate.

“Patent Rights” means any and all (i) national, regional and international patents and patent applications, including provisional patent applications (with the term patent deemed to include an inventor’s certificate, utility model and design model) and Unitary Patents; (ii) all divisionals, continuations, and continuations-in-part thereof; (iii) all patents issuing on any of the foregoing; and (iv) any and all extensions or restorations, including revalidations, reissues, re-examinations and any supplemental protection certificates of the foregoing (i), (ii) and (iii).

“Person” means any natural person, corporation, company, firm, partnership, business trust, joint venture, association, organization, or other similar entity or organization, including a government or political subdivision, department or agency of a government.

13/147

“ Phase 1 Study” means a clinical trial of a Product in humans, in any country that is intended to initially determine toxicity, metabolism, absorption, elimination and/or other pharmacological action consistent with 21 C.F.R. 312.21(a), or its successor regulation, or an equivalent Regulatory Authority of the Territory.

“Phase 1/2 Study” means a clinical trial that combines both a Phase 1 Study and a Phase 2 Study into a single protocol, where the Phase 1 Study portion is performed first to (a) establish initial safety, tolerability, pharmacokinetic and pharmacodynamic information for a Product as a monotherapy or in combination with another agent or (b) determine the optimal biological doses of such Product in subjects, and the Phase 2 Study portion is performed to further evaluate safety efficacy, pharmacokinetics and pharmacodynamics of such Product.

“Phase 2 Study” means, with respect to a Product, either a Phase 2A or a Phase 2B Study.

“Phase 2A Study” means a clinical trial of a Product in humans, the principal purposes of which are to evidence clinical activity of the Product, to determine its optimal dose and to obtain sufficient information on safety to permit the design of a Phase 2B Study, and which is consistent with 21 US C.F.R. § 312.21(b) or the regulations of the EMA or another equivalent Regulatory Authority in the Territory.

“Phase 2B Study” means a clinical trial of a Product in humans, the principal purposes of which are to make a preliminary determination that the Product is safe for its intended use, to determine its optimal dose, and to obtain sufficient information about such Product’s efficacy to permit the design of a Phase 3 Study, and which is consistent with 21 US C.F.R. § 312.21(b) or the regulations of the EMA or another equivalent Regulatory Authority in the Territory.

“Phase 3 Study” means an appropriately powered pivotal study in human patients with a defined dose or a set of defined doses of a Product which is designed to (i) demonstrate the efficacy and safety of such Product for an indication, and (ii) enable the preparation and submission of a NDA or other similar application for Regulatory Approval to the competent Regulatory Authorities in the Territory, and (b) is considered by the FDA (consistent with 21 US C.F.R. §312.21 (c)), EMA or other Regulatory Authority in the Territory to be a “Phase 3 Study”.

“Post Grant Proceeding” means any proceedings before any national patent authority involving the limitation, review, examination, analysis or any combination thereof, of any issued Patent Right. Examples of Post Grant Proceedings include patent limitation proceedings, post grant review proceedings, inter partes review proceedings, supplemental examination, patent interference proceedings, opposition proceedings initiated on and after issuance of the applicable Patent, reissue and reexamination.

“Pre-Development Candidate” means any Multispecific Antibody nominated as such by the JSC in accordance with the timeline and criteria set forth in the Work Plan.

“Pre-Hits” means any Multispecific Antibody nominated as such by the Project Leaders in accordance with the timeline and criteria set forth in the Work Plan.

“Pre-Selected Target�� means |||||||||||||||||||||||||||||||||||||||||.

“Product” means any pharmaceutical product (i) containing, as an active ingredient, any Multispecific Antibody targeting a Selected Target and (ii) which is claimed or disclosed by the Innate Patents and/or the Collaboration Patents, or which manufacture, use or sale would, absent the licenses granted to Sanofi hereunder, infringe the Innate Patents and/or the Collaboration Patents, and/or (iii) was developed with or uses any of the Innate Technology and/or Collaboration Technology. In this Agreement each Product

14/147

that contains as an active ingredient a different Candidate or Multispecific Antibody shall be regarded as a separate Product.

“Receiving Party” means the Party that receives Confidential Information from the other Party.

“Regulatory Approval” means any and all approvals (including any applicable supplements, amendments, pre- and post-approvals, governmental price and reimbursement approvals and approvals of applications for regulatory exclusivity), licences, registrations, or authorisations of any Regulatory Authority necessary for the manufacture, production, distribution or other transfer of possession, use. holding, storage, import, export, transport, promotion, marketing, labelling, supply or sale of a product in a country or jurisdiction in the Territory, or the use of a product in any pre-clinical or clinical study, or the collection, procurement, testing, use. analysis, processing, storage, import or export of human tissue samples, laboratory samples, or personal data in a country or jurisdiction in the Territory.

“Regulatory Authority” means any federal, national, multinational, international, supra-national, regional, state, provincial or local regulatory agency, department, bureau, commission, council or other governmental entity with authority over the manufacture, production, distribution or other transfer of possession, use. holding, storage, import, export, transport, promotion, marketing, labelling, supply, pre-clinical or clinical testing or sale of a Product or the collection, analysis, use. processing, testing, storage, import or export of human tissue or personal data.

“Research Program” means each program of research and non-clinical development activities directed to the discovery, testing and evaluation of Multispecific Antibodies suitable for selection as Candidates, including, without limitation, computer modeling, affinity modulation, in vitro and in vivo testing, biological research, assay development, and other early Development activities undertaken by the Parties pursuant to this Agreement during the Research Program Period.

“Research Program Period” has the meaning given to it in Section 4.4.

“Royalty Term” has the meaning given to it in Section 7.6.2.

“Sanofi Antibody” means Sanofi’s proprietary Antibody which binds to a Selected Target and is proposed by Sanofi and designated as such by the JSC.

|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

“Sanofi Commercialization IP” means (i) any Patents Rights (if any) or Know-How Controlled by Sanofi or its Affilihates or Sublicensees relating to the Commercialization of a Product; and (ii) Trade Marks Controlled by Sanofi or its Affiliates relating to or resulting from any Commercialization activity undertaken by Sanofi; and (iii) copyright or any other intellectual property analogous to copyright

15/147

including any rights in designs subsisting or relating to any (a) documents, designs or other embodiments of the trade dress for the Product including all packaging and labelling; or (b) any form of advertisement in whatever media or other marketing or promotional materials or any other intellectual property which in all cases are generated by or upon behalf of Sanofi or its Affiliates during the Term in connection with the advertising, promotion, marketing or sale or other Commercialization of a Product or are acquired by any of them in any manner for this purpose.

“Sanofi Development IP” means Patent rights, Materials and Know-How conceived, generated or otherwise developed by Sanofi, its Affiliates or Sublicensees, or acquired by Sanofi, its Affiliates or Sublicensees in any manner in connection with the Development of a Product but following completion of the relevant Research Program.

“Sanofi Format” means Sanofi’s proprietary Antibody Formats, as described in Schedule 3.1.1(b) as updated during the Research Program Period, including any specific and Non-Severable Modification or Improvement thereof conceived, discovered, generated, developed or otherwise made or acquired by either Party in the conduct of the activities pursuant to the Research Program during the Research Program Period.

“Sanofi IP” means the Sanofi Technology, the Sanofi Patents, Sanofi Development IP, Sanofi Commercialization IP, and all other Intellectual Property Rights in or to the Sanofi Technology or Sanofi Materials.

“Sanofi Indemnified Parties” has the meaning given to it in Section 11.2.

“Sanofi Materials” means with respect to any Research Program (i) any and all Materials Controlled by Sanofi at the Execution Date as listed in Schedule 3.1.1(b) as may be updated from time to time during the Term, (ii) any and all materials conceived, discovered, generated, developed or otherwise made or acquired solely by or on behalf of Sanofi outside of the conduct of its activities pursuant to the Research Program during the Research Program Period and contributed by Sanofi for use in the Research Program, (iii) Sanofi CMC Materials and (iv) any and all Materials, conceived, discovered, generated, developed or otherwise made or acquired in the conduct of its activities pursuant to the Research Program which are solely related to the Sanofi Technology, the Sanofi Format and/or the Sanofi Antibodies.

“Sanofi Option” has the meaning given to it in Section 4.1.

“Sanofi Option Notice” has the meaning given to it in Section 4.1.

“Sanofi Patents” means any and all Patent Rights Controlled by Sanofi or its Affiliates at the Execution Date or that claim an invention within the Sanofi Technology as listed on Schedule 3.1.1(b) hereto, as updated from time to time.

“Sanofi Senior Officer” has the meaning given to it in Section 5.1.4(d).

“Sanofi Technology” means, with respect to any Research Program, (i) all Know-How that is Controlled by Sanofi at the Effective Date or at the date it is contributed by Sanofi for use in the Research Program, (ii) the Sanofi CMC Technology and (iii) any Know-How that solely relates to the Sanofi Format and/or the Sanofi Antibodies and/or Sanofi Materials and is conceived, discovered, generated, developed or otherwise made, or acquired in the conduct of the Research Program(s).

“Selected Target” means B7H3 and any other targets for which Sanofi has exercised the Sanofi Option pursuant to Section 4.1, and paid the corresponding Option fee in accordance with Section 7.4.

16/147

"Strategic Reason" means ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

|||||||||||||||||||||||||||||||||||||||||||||||||||||||||

“Sublicensee” means a Third Party that is authorized by either Party to research, Develop or Exploit one or more Pre-Hit. Hit. Lead. Candidate or Product in the Territory (including any Third Party acting in collaboration with a Party or one of its Affiliates) in accordance with the terms of this Agreement. For sake of clarity, a Third Party Provider does not constitute a Sublicensee.

“to Target” or “Targeting” means, with respect to any target, to engage or engaging specifically such target via the corresponding ABD directed to such target.

“Term” has the meaning given to it in Article 12.

“Territory” means all countries of the world.

“Third Party” means any corporation, unincorporated organisation, Person or other legal entity other than Sanofi or Innate, or then respective Affiliates.

“Third Party Claim” has the meaning given to it in Section 11.3.

“Third Party Independent Designee” means a person selected by Innate and bound by written confidentiality obligations towards Sanofi and Innate, in charge of assisting the Parties in the target selection mechanism for Research Programs No. 2 and 3.

“Third Party Provider” has the meaning given to it in Section 4.12.1.

“Trade Mark” means any corporate name, trade name, trade dress, service mark, logos and trademarks (whether or not registered) and all applications for. and registrations of. and all renewals, extensions or modifications to. and any goodwill associated with, any of the foregoing in the Territory.

“Unified Patent Court” means the court established by the EU under the Unified Patent Court Agreement of 19 February 2013 (2013/C 175/01) (OJEU 20.6.2013, C 175/1).

“Unitary Patent” means those European patents which are subject to EU Regulation No 1257/2012 (OJ EUL361.31.12.2012.p. 1). A Unitary Patent may also be referred to as a European patent with unitary effect.

“United States” or “US” means the United States of America and all of its territories and possessions.

"Valid Claim" means |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

17/147

“Work Plan” has the meaning given to it in Section 4.3.

1.2 Interpretation

In this Agreement, unless the context otherwise requires:

1.2.1 references to “this Agreement” shall mean this Agreement and any and all Schedules to it, each as amended from time to time in accordance with the provisions of this Agreement;

1.2.2 references to a particular Article, Schedule or Paragraph shall be a reference to that article, schedule or paragraph in this Agreement unless expressly stated to the contrary;

1.2.3 words in the singular shall include the plural and vice versa and references to the masculine gender shall include the feminine gender and vice versa;

1.2.4 headings are for convenience only and shall be ignored in interpreting this Agreement;

1.2.5 the words “include”, “including” or “in particular” are to be construed without limitation to the generality of the preceding words;

1.2.6 references to a statute include any statutory modification, extension or re-enactment of that statute;

1.2.7 any reference to “writing” includes a reference to any communication effected by electronic transmission or similar means, including by email, unless expressly stated to the contrary;

1.2.8 the word “or” has the inclusive meaning represented by the phrase “and/or”; and

1.2.9 if there is any inconsistency between any Articles of this Agreement and any Schedule, such Articles shall prevail.

ARTICLE 2. RESEARCH COLLABORATION AND LICENSE GRANTS

2.1 Research Collaboration

The Parties agree to collaborate during the Research Program Period in the discovery, research and Development of Multispecific Antibodies with the objective to develop the First Product with respect to B7H3 and other Multispecific Antibodies Targeting up to two (2) other Selected Targets in accordance with the terms of this Agreement (the “Collaboration”).

18/147

2.2 License Grants

2.2.1 Licenses and Options Granted by Innate to Sanofi. Innate hereby grants to Sanofi and its Affiliates:

(a) an exclusive (even as to Innate and its Affiliates, subject to Section 2.2.2), transferrable (pursuant to Section 14.4), sublicensable (through multiple tiers in accordance with Section 2.2.3) and royalty bearing license under the Innate IP and Innate’s rights in the Collaboration Patents to research, Develop, Manufacture and Exploit Products and Multispecific Antibodies Targeting a Selected Target in the Field, in the Territory; and

(b) an exclusive option, exercisable under the conditions set forth in Section 4.1, for an exclusive (even as to Innate and its Affiliates, subject to Section 2.2.2), transferrable (pursuant to Section 14.4), sublicensable (through multiple tiers in accordance with Section 2.2.3) and royalty bearing license under the Innate IP and Innate’s rights in the Collaboration Patents to research, Develop, Manufacture and Exploit Multispecific Antibodies Targeting |||||||||||| in the Field, in the Territory; and

(c) an exclusive option, exercisable under the conditions set forth in Section 4.1, for an exclusive (even as to Innate and its Affiliates, subject to Section 2.2.2), transferrable (pursuant to Section 14.4), sublicensable (through multiple tiers in accordance with Section 2.2.3) and royalty bearing license under the Innate IP and Innate’s rights in the Collaboration Patents to research, Develop, Manufacture and Exploit Multispecific Antibodies Targeting ||||||||||||||||| in the Field, in the Territory; and

(d) a non-exclusive option, exercisable under the conditions set forth in Section 4.1, for an exclusive (even as to Innate and its Affiliates, subject to Section 2.2.2), transferrable (pursuant to Section 14.4), sublicensable (through multiple tiers in accordance with Section 2.2.3) and royalty bearing license under the Innate IP and Innate’s rights in the Collaboration Patents to research, Develop, Manufacture and Exploit Multispecific Antibodies Targeting a New Target in the Field, in the Territory; and

(e) an non exclusive option, exercisable under the conditions set forth in the next paragraph for a non-exclusive, transferrable (pursuant to Section 14.4), sublicensable (through multiple tiers in accordance with Section 2.2.3) and royalty bearing license under |||||||||||||||||||||||||||||||||||||||||||| Controlled by Innate at the time Sanofi exercises such option, solely to Exploit Pre-Hits, Hits, Leads, Pre-Development Candidates, Candidates and Back-Ups nominated by the Parties before the end of the Research Program Period, in the Field, in the Territory.

Sanofi’s option pursuant to this Section 2.2.1 (e) shall be exercisable with respect to any Pre-Hits, Hits, Leads, Pre-Development Candidates, Candidates and Back-Ups nominated by the Parties before the end of the Research Program Period by written notice of Sanofi to Innate given before the earlier |||||||||||||||||||||||||||||||||||||||||||||||||||

19/147

With respect to the option rights granted under b). c) and d) above, the Parties hereby understand and acknowledge that Sanofi may exercise its option right only twice, i.e for up to 2 additional targets in total (regardless of the type of target. Pre-Selected or New Targets).

2.2.2 Licenses and Option Granted by Sanofi to Innate. Sanofi hereby giants to Innate and its Affiliates, during the Research Program Period:

(a) a non-exclusive. royalty-free license, in the Territory, (i) under the Sanofi Patents and Sanofi’s rights in the Collaboration Patents and (ii) to use the Sanofi IP and the Collaboration IP. in each case under subclauses (i) and (ii) solely to conduct its activities pursuant to the Work Plan under the Research Program(s); and

(b) after such rights are licensed to Sanofi pursuant to Section 2.2.1. a non-exclusive. royalty-free license, in the Territory under Innate IP and Innate’s rights in the Collaboration Patents, solely to conduct its activities pursuant to the Work Plan under the Research Program(s).

2.2.3 Sublicensing rights

Dining the Research Program Period(s). each Party shall have the limited right to giant sublicenses of the rights granted to it by the other Party under Sections 2.2.1 and 2.2.2 to its Affiliates and/or to Third Party Providers to which they subcontract, in accordance with Sections 4.11 and 4.12, the responsibility to perform on their behalf any activities for which they are responsible under the Work Plan. Provided however that Sanofi may also giant sublicenses of its rights granted to it by Innate under Section 2.2.1

20/147

to (i) Third Party Providers to which Sanofi subcontracts any activities (except Commercialization activities) outside of the Work Plan, and (ii) Third Party academics with which Sanofi collaborates under the conditions (i) to (iii) set forth below.

After Candidate Nomination, Sanofi shall have the right to perform its obligations and exercise its rights pursuant to this Agreement through its Affiliates or Sublicensees provided that:

(i) Sanofi shall not grant any rights to a Sublicensee which are inconsistent with Sanofi’s rights and obligations under this Agreement, provided that, with respect to collaboration with academics, Sanofi may enter into such collaboration after the Research Program Period(s) under Sanofi’s standard terms and conditions that Sanofi applies to its own products as long as they are not substantially inconsistent with Sanofi’s rights and obligations under this Agreement;

(ii) Sanofi shall be at all times responsible for and liable to Innate under this Agreement with respect to the performance of such Affiliate or Sublicensee;

(iii) Sanofi shall inform Innate promptly upon or following the execution of a Sublicensing agreement with respect to the Development and Commercialization of a Product, provided that if such Sublicensing agreement is the subject of a public announcement either by Sanofi or by the Sublicensee, Sanofi shall, to the extent possible, inform Innate prior to such announcement, all subject to and in accordance with Applicable Laws.

2.2.4 Non-Compete and Restrictive Covenants

(a) Non-Compete and Restrictive Covenant

21/147

2.2.5 No Implied Rights

This Agreement confers no right, license, or interest by implication, estoppel, or otherwise under any Patents, Know-How, or other Intellectual Property Rights of either Party except as expressly set forth in this Agreement. Each Party hereby expressly retains and reserves all rights and interests with respect to Patents, Know-How, or other Intellectual Property Rights not expressly granted to the other Party hereunder.

2.2.6 Use - Limitations

If a Party uses the other Party’s Confidential Information and Intellectual Property Rights for other purposes than those permitted by this Agreement, any inventions or discovery resulting from such use shall be the sole property of the non-breaching Party and any information related to the non-breaching Party’s Confidential Information and Intellectual Property Rights resulting from such use shall be considered proprietary Confidential Information of the non-breaching Party and be held in confidence in accordance with this Agreement.

22/147

ARTICLE 3. TECHNOLOGY AND MATERIALS TRANSFER

3.1 Technology and Materials Transfer

3.1.1 Pre-Existing Technology and Materials

(a) The list and summary description of all Innate Technology and Innate Materials, as existing on the Execution Date, is attached as Schedule 3.1.1(a).

(b) The list and summary description of all Sanofi Technology and Sanofi Materials, as existing on the Execution Date, is attached as Schedule 3.1.1(b).

(c) The Parties agree to transfer to each other, within a reasonable time after the Effective Date, any Innate Materials and Sanofi Materials, as applicable, in reasonable quantities Controlled by a Party and necessary to the other Party to conduct its activities pursuant to the Research Program(s).

3.1.2 On-going Technology and Materials Transfer. During the Research Program Period, with respect to any given Research Program, on a quarterly basis, within |||||||||||||||||||||||||||| after the end of the relevant quarter:

(a) Innate shall provide to Sanofi a summary description of all Innate Technology and all Innate Materials conceived, developed, generated, made or otherwise coming into Innate’s possession in the conduct of the Research Program during such quarter that are necessary or reasonably useful for the research, Development, Manufacturing and Exploitation of any Multispecific Antibodies Targeting a Selected Target or Products, and on request, shall provide Sanofi with copies of all such Innate Technology and/or descriptions of all such Innate Materials; Provided however that Innate shall not be obliged to disclose details of Innate CMC Materials and Innate CMC Technology;

(b) Sanofi shall provide to Innate a summary description of all Sanofi Technology and all Sanofi Materials conceived, developed, generated, made or otherwise coming into Sanofi’s possession in the conduct of the Research Program during such quarter that are necessary or reasonably useful to Innate to conduct its activities pursuant to the Work Plan, and on request, shall provide Innate with copies of all such Sanofi Technology and/or descriptions of all such Sanofi Materials; Provided however that Sanofi shall not be obliged to disclose details of Sanofi CMC Materials and Sanofi CMC Technology;

(c) Each Party shall provide to the other all Collaboration Technology conceived, developed, generated or otherwise made during such quarter; and a description of all Collaboration Materials conceived, developed, generated or otherwise made during such quarter; and

(d) At each meeting of the JPT, each Party shall disclose to the JPT details of any Collaboration Materials, Sanofi Materials and Innate Materials conceived, developed, generated or otherwise made by it in the conduct of the Research Program since the previous JPT meeting that are, with respect to Sanofi Materials and Innate Materials, necessary or reasonably useful for the research, Development, Manufacturing and Exploitation of any Multispecific Antibodies Targeting a Selected Target or Products. The JPT shall determine which of these Collaboration Materials, Sanofi Materials and Innate Materials should be transferred to the other Party and shall agree upon a transfer plan

23/147

for such Collaboration Materials, Sanofi Materials, or Innate Materials, as applicable.

3.1.3 Secure access

Within |||||||||| ||||||||||||||||||| of the Effective Date, the Alliance Managers shall agree and implement secure access methods (such as secure databases or other secure on-line data sharing systems) to allow each Party’s Scientific Team working on the Research Program to share Collaboration Technology, details of Collaboration Materials, Innate Technology, details of Innate Materials, Sanofi Technology, and details of Sanofi Materials. Each Party shall upload a summary description of all relevant Information and Materials. Each Party shall upload periodically all scientific results obtained in the course of the execution of the Work Plan. Each Party shall use electronically accessible formats (e.g. Excel, CSV or SDF).

3.2 Assistance

During the Research Program. Period, each Party shall, at its own costs and at the other Party’s request, provide reasonable assistance to the requesting Party with respect to the use of such Party’s Technology and Materials or Collaboration Technology and Materials.

ARTICLE 4. RESEARCH COLLABORATION

4.1 Research Program(s) and Sanofi Option

On the Effective Date, the Collaboration includes one Research Program directed to the testing and evaluation of the First Product (“Research Program No. 1”).

Until:

(a) with respect to a Pre-Selected Target, the earlier of (i) the||||||| anniversary date of the Effective Date of the Agreement or (ii) the expiration of the ||||||||||||||||||||||||||||| following the provision by Innate of all documents and data listed on Schedule 4.1 (the “Option Data Package”); or

(b) with respect to any other target suggested by Innate or selected pursuant to the target selection process described below in Section 4.2 (a “New Target”), the ||||||| anniversary date of the Effective Date of the Agreement;

(a and b the “Option Period”), Sanofi will have the option (the “Sanofi Option”) to include up to two (2) other Research Programs (respectively, “Research Program No. 2” and “Research Program No. 3” and jointly, “Research Programs No. 2 and No. 3”) in the Collaboration directed to the discovery, testing and/or evaluation of a Multispecific Antibody Targeting a Pre-Selected Target or a New Target, and to be granted the corresponding exclusive license.

For the avoidance of doubt, while Innate shall use Commercially Reasonable Efforts to deliver the Option Data Package, it cannot guarantee that such Option Data Package can be delivered. In the event the Option Data Package is unlikely to be achieved for scientific or technical issues within the above timeline or at reasonable costs for Innate, Innate may, after consulting with Sanofi, cease the activities supporting the obtention of the Option Data Package, and the Option Period will then expire on the 3rd anniversary date of the Effective Date of the Agreement.

24/147

Sanofi may elect to exercise the Sanofi Option, by sending a written notice to Innate on or before the last day of the Option Period (the “Sanofi Option Notice”).

4.2 New Target Selection Process

In order to preserve the confidentiality of Innate’s pre-existing agreements with Third Parties at the time of the exercise of the Sanofi Option with respect to a New Target, Innate and Sanofi shall have entered into an agreement with a Third Party Independent Designee. Such agreement shall include, in addition to standard provisions typically included in such type of agreements, the following provisions: During |||||||||||||||||||||||||||||||| after the Effective Date, Sanofi may submit by written notice to the Third Party Independent Designee the name of the targets intended to be selected by Sanofi to be paired with the Innate Multispecific Antibody (“Sanofi Request”) and within two (2) Business Days of receipt of such notice, Innate shall deliver to the Third Party Independent Designee a list of targets that are not available to be exclusively licensed to Sanofi pursuant to this Agreement because they are the subject of an internal program by Innate or an agreement between Innate and a Third-Party. Both lists shall be kept confidential by the Third Party Independent Designee. Within |||||||||||||||||||||||||||||||| of receipt of both the Sanofi Request and Innate’s list, the Third Party Independent Designee shall indicate in writing to Sanofi if the target proposed by Sanofi is available. If the target proposed by Sanofi is available, Sanofi may exercise its Sanofi Option and the Parties will discuss the subject of a Research Program.

4.3 Work Plan

4.3.1 All activities to be carried out by or on behalf of either Party (and/or its respective Affiliates, Sublicensees or other Third Party Providers) under a Research Program during the Research Program Period, shall be set forth in a written work plan (the “Work Plan”). The Work Plan shall set out the research activities assigned to each of the Parties and anticipated timelines for the completion of such activities, as well as objective criteria to assess whether the activities set out in the Work Plan have been completed. The initial Work Plan with respect to Research Program No 1 is agreed between the Parties and attached as Schedule 4.3 hereto. As soon as reasonable following the exercise of the Sanofi Option with respect to any additional Research Program, the Parties shall agree on a Work Plan for such additional Research Program (including anticipated timelines and objective success criteria for the completion of such activities in furtherance of such Research Program).

4.3.2 After the Effective Date, the Work Plan shall be reviewed and amended as needed by the JSC in accordance with Section 5.1.6(a) of this Agreement at the request of either Party through the JPT, and in any event at least once a year. Within ||||||||||||||||||||||||||||||||| of the request of either Party through the JPT, the JSC shall meet and assess whether the activities set out in the current Work Plan have been completed according to the criteria set out in such Work Plan and discuss any proposed amendment to the Work Plan. Without limiting the foregoing with respect to any interim adjustment to the Work Plan, the JSC shall adopt the amended Work Plan for the following twelve month’s period at least ninety (90) days before the end of each calendar year.

25/147

4.4 Research Program Period

Research Program No. 1 shall commence on the Effective Date and expire upon the earlier of (i) a Candidate Nomination by the JSC in accordance with this Agreement and (ii) |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| subject to any extension of such period by the JSC (the “Research Program Period”). If Sanofi exercises the Sanofi Option, the Research Program Period for Research Programs No. 2 and Research Program No. 3 shall commence on the date of the adoption by the JSC of the Work Plan with respect to Research Program No. 2 or Research Program No. 3, and shall expire upon the earlier of ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

4.5 Nomination Process for Pre-Hits, Hits, Leads, Pre-Development Candidates, Candidates and Back-Ups

4.5.1 During the Research Program, the Pre-Hits and Hits will be nominated by mutual agreement of the Project Leaders without escalation to the JSC.

4.5.2 Leads, Pre-Development Candidates, Candidates as well as any Back-Ups will be nominated by the JSC among molecules selected by the Project Leaders.

4.5.3 In case of disagreement between the Project Leaders or at the JSC, the nomination of Leads, Pre-Development Candidates, Candidates, as well as Back-Ups will be decided pursuant to 5.1.4(d)(ii).

4.5.4 Provided that all documents and data listed on Annex 1 of the Work Plan within Innate’s responsibilities (the “Nomination Data Package”) have been made available to Sanofi on or prior to the last day of the Research Program Period, (i) the JSC shall meet to decide upon the nomination of a Candidate for each Research Program and (ii) the Parties shall adopt the final minutes of such meeting on or before ||||||||||||||||||||||||||||||||||| following the JSC meeting.

4.5.5 In the event the JSC (i) does not nominate a Candidate because the Candidate Nomination criteria set forth in the Nomination Data Package are not met and (ii) does not extend the Research Program Period as a result of a refusal of Innate, then Sanofi upon prior written notice to Innate within |||||||||||||||||||||||||||||| following the adoption of the final minutes by the JSC (“Continued Development Notice”), will be entitled to continue to work towards nominating a Candidate at Sanofi’s sole cost until such Candidate Nomination criteria set forth in the Nomination Data Package are met, at which point the Candidate will be nominated by Sanofi. Until the Candidate Nomination, Sanofi shall (x) continue to use Commercially Reasonable Efforts with respect to nominating a Candidate and (y) comply with the audit and reporting obligations set out in Sections 4.8 and 4.9 and (z) at Innate’s request, cause their employees directly involved in these activities to participate in a video meeting to discuss in good faith each semi-annual report submitted in accordance with Section 4.8. Sanofi shall send a written notice informing Innate that the corresponding Candidate Nomination milestone has been achieved within |||||||||||||||||||||||||||||| of such nomination.

4.5.6 In the event the JSC (i) does not nominate a Candidate because the Candidate Nomination criteria set forth in the Nomination Data Package are not met, and (ii) does not extend the Research Program Period, and (iii) Sanofi does not provide a Continued Development Notice within |||||||||||||||||||||||||||||||||| following the adoption of the

26/147

final minutes by the JSC, then the Candidate Nomination milestone will be deemed achieved and Sanofi shall pay the corresponding amount as set forth in Section 7.5.1.

4.5.7 The Parties shall make their best efforts to complete all documents and data listed in Annex 1 to the Work Plan resulting from the conduct of their respective activities within thirty-six (36) months of the Effective Date for Research Program No. 1 and within thirty-six (36) months of the date of the exercise of the Sanofi Option for Research Program No. 2 and Research Program No. 3.

4.6 Performance Generally

4.6.1 Each Party shall make available and maintain sufficient resources and qualified personnel to execute the activities allocated to it pursuant to the current Work Plan substantially in accordance with the planning and objectives of the Work Plan, in a good scientific manner and in order to ensure that all Information, data, and Collaboration Materials produced by such Party is accurate and complete in all material respects. The Parties shall monitor the performance of their respective activities through the JSC. Each Party will promptly inform the other Party in writing in the event that it becomes aware of any facts or circumstances which may cause it to be unable to timely perform any of the activities or other obligations for which it is responsible under the Work Plan. The JSC shall then promptly meet to discuss the situation and agree upon mutually acceptable steps to address the performance concerns identified by such Party so as to avoid any delays or other material adverse effects on the Research Programs.

4.6.2 The Parties shall perform the activities under the Work Plan for which it is responsible using its best efforts and in compliance with: (i) the terms of this Agreement, (ii) the Work Plan (including as it may be amended), and (iii) all Applicable Laws, including those pertaining to GCPs, GLPs and GMPs.

4.7 Records

Each Party shall maintain records in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, and in compliance with Applicable Laws.

4.8 Progress Reports and Forecasts

On a semi annual basis, each Party shall provide reports through a presentation to the JSC, which shall set forth in reasonable detail all data and information generated or obtained in the course of such Party’s performance of the Research Program(s). Concomitantly, each Party shall also provide a more detailed written report to the JSC, which report should set forth a detailed summary of all data and information generated or obtained during the past year, as well as a forecast (including timelines and budgets) of the activities and milestones to be achieved during the next eighteen (18) months pursuant to the Work Plan. The format and content of such reports will be detailed in the Work Plan.

4.9 Audit rights

During the Research Program Period, once per calendar year, each Party shall have the right, upon |||||||||||||||||||||||||||||||||||||||||| advance written notice, to access the premises of the other Party and all laboratory note books and other documents pertaining to the Work Plan to assess whether the other Party has provided all Collaboration Technology and all descriptions of all Collaboration Materials generated by such Party in a timely manner. The cost thereof shall be borne by the Party that has conducted the audit

27/147

unless such audit reveals a material breach by the other Party in which event the costs of such audit shall be borne by the other Party.

4.10 Animal Welfare

Should any Research Program include experimentation on animals, each Party undertakes (i) to comply with the "Sanofi Policy on Animal Protection” attached hereto as Schedule 4.10, and (ii) to follow their respective internal approval process, if any, prior to the initiation of such experimentation activities.

4.11 Performance by Affiliates

At a Party’s election, any specific activities for which such Party is responsible under this Agreement may be performed on such Party’s behalf by one or more of its Affiliates; provided that such Party shall control and remain responsible hereunder for the performance of such Affiliates.

4.12 Subcontracting

4.12.1 Either Party may perform any specific activities for which it is responsible in connection with any Research Program or the Development and/or Manufacturing and/or Commercialization of any Materials and Products pursuant to this Agreement through subcontracting to an Affiliate or a Third Party (a “Third Party Provider”) (including a contract service organization, contract research organization, contract manufacturing organization or contract sales force) provided that during the Research Program Period, but except, with respect to Sanofi, for CMC Activities and clinical development preparatory activities, each Party shall obtain the prior written consent of the other Party with respect to (i) the activities to be subcontracted, (ii) the selected Third Party Provider and (iii) the material terms and duration of the contract.

4.12.2 The subcontracting Party shall: (i) ensure that any Third Party subcontractor to whom a Party discloses Confidential Information of the other Party is bound by an appropriate written agreement obligating such Third Party Provider to obligations of confidentiality and restrictions on use of the other Party’s Confidential Information that are at least as stringent as the confidentiality obligations under this Agreement; (ii) ensure that such Affiliate or Third Party Provider is bound in writing to assign to such Party any inventions (and any related Intellectual Property Rights covering such inventions) made by such Third Party Provider or its employees or agents in performing such services for such Party that are necessary to the research, Development, Manufacturing or Commercialization of Materials or Products; and (iii) at all times be responsible for and liable to the other Party under this Agreement with respect to the performance of such subcontractor.

ARTICLE 5. GOVERNANCE OF THE COLLABORATION

5.1 Joint Scientific Committee

5.1.1 Establishment and Objectives

As soon as reasonably practicable after the Effective Date and in any event within two (2) weeks after the Effective Date, the Parties shall establish a Joint Scientific Committee (the "JSC") to oversee the performance of each of the Research Programs during the corresponding Research Program Period.

28/147

5.1.2 Composition

The JSC shall initially be composed of 2 representatives of each Party to be appointed by each Party within |||||||||||||||||||||||||||||| of the Effective Date. Such number may be reduced or increased by mutual agreement of the Parties; provided that, in any event, each Party shall have an equal number of representatives. Each Party may (i) replace one or more of its representatives on the JSC or (ii) appoint a substitute to represent a JSC member at a particular meeting, in each case subject to prior written notice to the other Party. All JSC members and their substitutes shall have appropriate expertise, seniority, decision making authority, and ongoing familiarity with the Research Program(s).

5.1.3 Meetings

While in existence, the JSC shall meet at regular intervals to be determined by the JSC, but no less than semi-annually. Either Party may call a meeting of the JSC if this Agreement requires a matter to be considered or determined by the JSC.

The JSC meetings may take place by audio, video teleconference or in person as determined by the JSC members.

5.1.4 Quorum, Voting and Escalation

(a) For each meeting of the JSC, the attendance of at least one (1) representative of each Party shall constitute a quorum. Each Party agrees to use Commercially Reasonable Efforts to ensure that at least one of its representatives will be present at each JSC Meeting.

(b) Decisions of the JSC shall be made by consensus, with the representatives of each Party having collectively one vote on behalf of such Party or by a written consent outside of a meeting signed by all JSC representatives of each Party.

(c) Each Party may invite additional employees or consultants to attend meetings of the JSC with the other Party’s prior consent but any such additional attendees shall not have any right to vote.

(d) Escalation. If the JSC is unable to agree on any matter for which it has received decision making authority pursuant to this Agreement, the Alliance Manager in charge of the minutes of such JSC meeting pursuant to Section 5.1.5 below shall record such dispute in such minutes. If, within |||||||||||||||||||||||||||||||||| (or such longer period of time as the Parties may agree) after such minutes were first circulated to the JSC members for approval, the JSC members fail to resolve such dispute, it shall be escalated by the Alliance Managers of each Party to the CEO of Innate and to a senior officer of Sanofi having significant expertise in and knowledge of the Research Program(s), (a “Sanofi Senior Officer”), to be resolved by good faith discussion and agreement between them. If the CEO of Innate and the Sanofi Senior Officer cannot reach agreement on such matter within |||||||||||||||||||||||||||||||||||||||||||||||||||||||||after such referral:

29/147

(i) If such dispute relates to (A) the extension of the Option Period or the Research Program Period, (B) any amendment to the Work Plan to the extent such amendment increases Innate’s costs and Sanofi is not willing to cover such costs or requires Innate to commit an additional three (3) or more FTEs in addition to the maximum number of FTEs dedicated to conduct Innate’s obligations under the Work Plan in the preceding 12 months; (C) any proposal to determine if any Material shall be deemed to be Sanofi Material, Innate Material, Collaboration Material, Innate Format or Sanofi Format pursuant to this Agreement, (D) any proposal that would increase Innate’s obligations or costs hereunder except as otherwise permitted under (B); or (E) any proposal that would require Innate to take any action that would result in a violation of Applicable Laws or of any agreement with any Third Party or the infringement of intellectual property rights of any Third Party, all matters related therewith shall require mutual consent of the Parties acting in good faith; and

(ii) With respect to all other matters not listed under Section 5.1.4(d)(i) above, Sanofi shall be entitled to make the final determination with respect to any such matter for which the JSC has received decision making authority pursuant to this Agreement (including for the avoidance of doubt, in respect of the nomination of Leads, Pre-Development Candidates, Candidates, and Back-Ups), provided that Sanofi shall have no authority to impose any requirements on Innate to undertake obligations or incur liabilities, except as otherwise permitted under Section 5.1.4(d)(i)(B) above, beyond those for which it is responsible pursuant to this Agreement (including the current Work Plan), nor to waive any of Innate’s rights pursuant to this Agreement.

5.1.5 Agenda and Minutes

At least |||||||||||||||||||||||| prior to each JSC Meeting, a Party through its Alliance Manager, will prepare and circulate for review and approval to the JSC members a meeting agenda which shall include any agenda items that the other Party requests to be added and will prepare and circulate minutes of such meeting for review within |||||||||||||||||||||||||||||||||||||| after the JSC meeting. While the JSC is in existence, the Parties shall alternate being responsible for such preparation and circulation of the agenda for each JSC meeting.

The minutes shall be prepared by the Alliance Manager of the Party who was in charge of the agenda and shall record accurately all proposed decisions, recommendations, and final decisions of the JSC. The Parties will in good faith use their best efforts to agree on the minutes of each meeting promptly upon distribution of such minutes but in no event later than |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| after such distribution by the Secretary. The final minutes shall be deemed approved by the Parties if approved in writing by both Alliance Managers.

5.1.6 Responsibilities

Except as otherwise provided in this Agreement, the JSC shall oversee and provide strategic guidance in connection with the implementation of the Work Plan and the conduct of the Research Program(s). Specifically, and in addition to any other responsibilities assigned to the JSC elsewhere in this Agreement, the JSC shall be responsible for:

(a) reviewing and approving any amendments to the Work Plan including upon

30/147

the initiation of Research Programs No. 2 and Research Program No. 3;

(b) overseeing the conduct of Research Program(s) activities and approving decisions to subcontract Research Program activities on behalf of both Parties in accordance with Section 4.12;

(c) monitoring progress of the Research Program(s) and nominating Leads, Pre-Development Candidates, Candidates, and Back-Ups pursuant to the Work Plan;

(d) reviewing all strategic issues arising with respect to any Research Program and serving as a forum for discussing such issues including issues related to the filing of Collaboration Patents;

(e) resolving any dispute referred to it by the Alliance Managers that are related to the Work Plan in accordance with Section 5.1.4(d);

(f) deciding upon any other matters subject to JSC decision pursuant to this Agreement, or as the Parties may agree in writing from time to time;

(g) forming sub-committees and delegate part of its responsibilities; provided however that, such sub-committees may not make any decision in lieu of the JSC.

5.1.7 Costs and expenses

Each Party shall bear its own travel costs and expenses in relation to any meetings of the JSC.

5.2 Joint Project Team

5.2.1 A joint project team (the “Joint Project Team” or “JPT”) will be formed by the Parties within one (1) month of the Effective Date and will consist of scientists of each Party and one (1) project leader of each Party (each a “Project Leader”).

5.2.2 The Joint Project Team members will be proposed by the Project Leaders and approved by the Program Managers. There shall be no pre-determined number of Joint Project Team members, and the number of Joint Project Team members need not be evenly divided between the Parties.

5.2.3 Each Party shall promptly notify the other Party of the appointment and any subsequent replacement of its Joint Project Team members and Project Leader.

5.2.4 The Joint Project Team will be responsible for designing, planning, coordinating and executing the Research Program(s) and generally managing the day-to-day Research Program activities to ensure progress in accordance with the Work Plan.

5.2.5 The JSC will decide whether or not a new Joint Project Team shall be formed upon the initiation of Research Program No. 2 or Research Program No. 3.

31/147

5.2.6 The Project Leaders will be in charge of the scientific leadership of the Research Program and will co-lead the Joint Project Team. They will nominate Pre-Hits and Hits, based on the recommendations of the Joint Project Team. They will make the final decision by consensus on the molecules submitted to the JSC as Leads and Candidates as well as Back-Ups, based on recommendations of the Joint Project Team. The Project Leaders will consult with the Program Managers with respect to Research Program activities, timelines, and resources as well as for publication and patenting proposals, to be submitted to the JSC.

5.2.7 The Joint Project Team will meet on a regular basis and at least every two (2) months, at such time and place as agreed upon by the Program Managers of each Party, either in-person, by telephone or video conference, to share and discuss the progress of the Research Program(s) since the last Joint Project Team meeting. The Joint Project Team meetings will be co-chaired by the Program Managers of each Party.

5.2.8 The Joint Project Team will prepare written reports for the JSC on the progress and results of its Research Program. The Parties will alternate preparing written reports of the Joint Project Team meetings.

5.3 Program Managers

Within one (1) month of the Effective Date, the Parties will nominate a Program Manager. The Program Managers will ensure the coordination of the Parties’ activities and responsibilities in furtherance of the Work Plan. They will work closely with the Project Leaders and manage the operational aspects of the Research Programs. The Program Managers shall ensure that the Research Programs progress in accordance with the Work Plan and shall liaise with the Alliance Managers to keep them informed of such progress. The Program Managers will attend JSC meetings as non-voting participants. They will organize Joint Project Team meetings and will write the minutes of these meetings.

5.4 Alliance Managers

5.4.1 Upon the Effective Date, each Party will appoint an individual employee representative to serve as liaisons between the Parties with respect to the Collaboration and to promote effective communication between the Parties (the “Alliance Managers”). The Alliance Managers will serve as primary contact persons with respect to the governance of the Collaboration including facilitating effective exchange of information and discussing the performance of the Parties under this Agreement as well as in relation to external communications. The Alliance Managers will coordinate and attend all meetings of the JSC and will be responsible for the preparation and circulation of JSC meeting minutes for approval and will facilitate the scheduling and conduct of JSC meetings as set forth in Section 5.1.5. The Alliance Managers will also (i) be responsible for the launch of the Collaboration, (ii) ensure that relevant action items resulting from such JSC meetings are appropriately carried out or otherwise addressed, (iii) identify and serve as the initial point of contact with respect to any dispute related to the conduct of the Research Program and bring any such disputes to the attention of the JSC in a timely manner, and (iv) bring any matter to the attention of the relevant sub-committee formed by the JSC pursuant to Section 5.1.6(g), if any.

32/147

5.4.2 Between two annual reports delivered by Sanofi pursuant to Section 6.7, prior to the First Commercial Sale of a Product with respect to each Research Program, the Sanofi Alliance Manager will be responsible to reasonably answer Innate’s requests within a reasonable time following such request for information regarding the progress of the Development and registration of the Product within such Research Program.

5.4.3 The Alliance Managers may not be members of the JSC nor of the Joint Project Team, nor will they have any voting rights or decision making authority with respect to matters for which such committees are responsible.

5.4.4 Upon the expiration of each Research Program Period, after the disbandment of the relevant JSC, the Alliance Managers shall continue to serve as liaisons between the Parties to coordinate and facilitate communications and reporting between the Parties hereunder.

ARTICLE 6. DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION

6.1 Overall Responsibility

6.1.1 Upon the expiration of a Research Program Period and during the Term, Sanofi may (without prejudice to Sanofi’s diligence obligations pursuant to Section 6.6) research, Develop, Exploit, Manufacture and Commercialize any and all Multispecific Antibodies that bind to the corresponding Selected Target, including Pre-Hits, Hits, Leads, Pre-Development Candidates, Candidates, any Back-Ups and any Products in the Field and in the Territory, at its sole cost and expense and in its sole discretion, subject to the terms and conditions of this Agreement.

6.1.2 Sanofi shall have the right to perform its obligations and exercise its rights pursuant to this Article 6 through its Affiliates, Third Party Providers or Sublicensees subject to Section 0.

6.1.3 Upon request of Sanofi, Innate shall use Commercially Reasonable Efforts to provide Sanofi with reasonable technical support and quantities of Innate Materials to the extent such Innate Materials are available and reasonably useful for the Development and Manufacture of Multispecific Antibodies that bind to a Selected Target. Sanofi shall pay Innate for Innate Materials to the extent additional manufacturing is required.

6.2 Development

Upon the expiration of a Research Program Period, Sanofi will be solely responsible for the Development in the Field of all Candidates and Products including for all decisions with respect to the conduct of clinical trials.

6.3 Regulatory Approvals

6.3.1 Sanofi shall have the sole right to and shall be solely responsible for (i) the preparation and submission, at its own expense, of all applications for any Regulatory Approvals required for the Commercialization of any Product in the

33/147

Field in any country in the Territory, (ii) for maintaining any and all Regulatory Approvals obtained for any Product, and (iii) for all Product-related communications with Regulatory Authorities.

6.3.2 Innate shall, at Sanofi’s cost (as to reasonable and properly incurred out-of-pocket expenses only), provide such assistance as Sanofi may reasonably require of Innate in connection with such activities. All Regulatory Approvals with respect to any Product shall be owned by Sanofi.

6.4 Manufacturing

Upon expiration of a Research Program Period, Sanofi shall have the sole right and shall be solely responsible for, developing the manufacturing process for each corresponding Candidate and Product and for manufacturing or having manufactured such Candidates or Products, at its own cost and expense.

6.5 Commercialization

Sanofi shall have sole responsibility and sole control over Commercialization activities with respect to any Product.

6.6 Diligence

Sanofi shall use its Commercially Reasonable Efforts to Develop and Commercialize at least one Product per Selected Target, for use in the Field, in the Major Market Countries.

6.7 Reporting

During the Term and after the expiration of a Research Program Period, Sanofi shall deliver annually to Innate, within ||||||||||||||||||||||||||||||||||| of each anniversary of the Effective Date, a reasonably detailed written report summarizing the Development, Manufacturing and Commercialization activities conducted by or on behalf of Sanofi with respect to any Candidates and Products hereunder in order to demonstrate to Innate that Sanofi is using Commercially Reasonable Efforts to Develop and to Commercialize one or more Products, provided that Sanofi shall not be obliged to disclose any of its Confidential Information in such report.

ARTICLE 7. FINANCIAL PROVISIONS

7.1 Research Program Costs

Unless otherwise agreed in writing between the Parties, each Party shall bear its own costs and expenses incurred in conducting the activities allocated to it pursuant to the Work Plan, as amended from time to time, pursuant to this Agreement.

7.2 Development, Manufacturing and Commercialization Costs

Sanofi shall be solely responsible for all Development, Manufacturing, regulatory and Commercialization costs with respect to any Candidate or Product.

7.3 Upfront Payment

34/147

In partial consideration of the rights and licenses granted by Innate to Sanofi hereunder and subject to the terms and conditions of this Agreement. Innate will invoice Sanofi promptly on or after the Effective Date, and Sanofi will pay to Innate a one-time non-refundable, non-creditable payment of twenty-five million Euros (€25,000,000) within ||||||||||||||||||||||||||||||||||||||||||||||||||||||| following the receipt of such invoice.

7.4 Option Fee

With respect to any additional Selected Target, i.e other than B7H3. on a target-by-target basis, Innate will invoice Sanofi promptly on or after the receipt of the Sanofi Option Notice, and Sanofi will pay to Innate the corresponding Option fee within |||||||||||||||||||||||||||||||||||||||||||||||||||| following the receipt of such invoice.


Target			Option Fee
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|

The Option fee shall not be refundable or creditable against any other payments Sanofi is obligated to make to Innate under this Agreement.

For the sake of clarity, upon payment of the Option fee. the Pre-Selected Target or New Target for which Sanofi exercised its Option will become a Selected Target.

7.5 Milestones Payments

7.5.1 Candidate Nomination Milestone

Innate shall invoice Sanofi for the following non-refundable and non-creditable milestone payments upon the first Candidate nomination in accordance with Section 4.5 of this Agreement with respect to each Selected Target (the “Candidate Nomination”), on a Selected Target per Selected Target basis and Sanofi shall pay such invoice within ||||||||||||||||||||||||||||||||||||||||||||||||| of its receipt.


Selected Target			First Candidate Nomination Milestone
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|

The Candidate Nomination milestone payments shall only be payable once for each Selected Target and no additional payment shall be due in the event of any repeated occurrence of the same event, such that the aggregate amount of Candidate Nomination milestone payments due to Innate shall not. under any circumstances, exceed |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| in aggregate, for all Selected Targets.

7.5.2 Pre-Clinical Milestone

Sanofi shall send a written notice informing Innate within |||||||||||||||||||||||||| of the dosing of the fir st animal in the first GLP-Tox Study with respect to the first Candidate with respect to each Selected Target, Innate shall invoice Sanofi for a non-refundable and non-creditable milestone payment equal to ||||||||||||||||||||||||||||||||||||||||||||||||||| of its receipt (the “GLP-Tox Milestone Payment”), on a Selected Target per Selected Target basis and Sanofi shall pay such invoice within ||||||||||||||||||||||||||||||||||||||||||||||||| of its receipt.

35/147

The GLP-Tox Milestone Payment shall only be payable once with respect to each Selected Target and no additional payment shall be due in the event of any repeated occurrence of the same event, such that the aggregate amount of GLP-Tox Milestone Payments due to Innate shall not, under any circumstances, exceed ||||||||||||||||||||||||||||||||||||||||||||||||| in aggregate, for all Selected Targets.

7.5.3 Clinical Development Milestones

Sanofi shall send a written notice informing Innate within ||||||||||||||||||||||||||| of the achievement of the following clinical development milestones by a Product Targeting a Selected Target. Innate shall invoice Sanofi for the following corresponding clinical development milestone payments promptly on or after the receipt of such written notice and Sanofi shall pay such invoice within ||||||||||||||||||||||||||||||||||||||||||||||||| of its receipt.


\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|

The clinical development milestone payments shall only be payable once for each Selected Target and no additional payment shall be due in the event of any repeated occurrence of the same event, such that the aggregate amount of clinical milestone payments due to Innate shall not. under any circumstances, exceed (i) |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| for all Products Targeting B7H3, (ii) |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| for all Products Targeting a Pre-Selected Target, and (iii) ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| for all Products Targeting a New Target.

36/147

7.5.4 Regulatory Milestones

Sanofi shall send a written notice informing Innate within ||||||||||||||||||||||||||||| of the achievement of the following regulatory milestones by a Product Targeting a Selected Target. Innate shall invoice Sanofi for the following corresponding regulatory milestone payments promptly on or after the receipt of such written notice, and Sanofi shall pay such invoice within ||||||||||||||||||||||||||||||||||||||||||||||||| of its receipt.


\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|

* If a conditional or accelerated approval is granted, then ||||||||||||||||||||||||||||||||||||||||||||||||| of the milestone payment will become payable upon the conditional or accelerated approval and |||||||||||||||||||||| of the milestone payment will become payable upon full approval.

The regulatory milestone payments shall only be payable once for each Selected Target and no additional payment shall be due in the event of any repeated occurrence of the same event, such that the aggregate amount of regulatory milestone payments due to Innate shall not, under any circumstances, exceed ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| in aggregate, for all Selected Targets.

7.5.5 Commercial Sales Milestones

Subject to any adjustments which may be required pursuant to Section 7.6.3. Sanofi shall pay to Innate each of the following Commercial Sales milestone payments upon the first occurrence of the corresponding milestone event by all Products Targeting a Selected Target.


\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|

37/147


	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|

Each of the foregoing Commercial Sales milestone payments shall only be payable once during the Tenn and no additional payment shall be due in the event of any repeated occurrence of the same event, such that the aggregate amount of Commercial Sales milestone payments due to Innate shall not. under any exceed |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| in aggregate, for all Selected Targets.

The achievement of any of the foregoing Commercial Sales Milestone Events will be notified by Sanofi to Innate upon the delivery to Innate of the annual report summarizing the Net Sales of Products, on a Selected Target per Selected Target basis as set forth in Section 7.6.4. for the last Calendar Quarter of each Calendar Year during which such milestone was achieved.

Notwithstanding the foregoing, if, for a given year, Sanofi’s semi-annual report summarizing the Net Sales of Products shows that a Commercial Sales Milestone Event has been achieved during the first two Calendar Quarters of such year, then Sanofi shall notify such achievement to Innate upon the delivery of the semi-annual report to Innate.

For clarity, if this Agreement is terminated before the delivery by Sanofi of the annual report summarizing the Net Sales of Products for a Calendar Year and such report shows that a Commercial Sales Milestone Event has been achieved prior to such termination, then such achievement shall be notified by Sanofi to Innate and the corresponding milestone payment shall be due and payable by Sanofi to Innate notwithstanding such termination.

Innate shall invoice Sanofi for the corresponding sales-based milestone payments at the same time as it invoices Sanofi for the Royalty Payment corresponding to such Calendar Quarter pursuant to Section 7.6.4 and Sanofi shall pay such invoice within |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| of its receipt.

7.6 Royalties

7.6.1 Royalty Rates

On a Selected Target per Selected Target basis and country-per-country basis. Sanofi shall pay royalties to Innate, at the rates shown hereunder for each corresponding tier of worldwide Annual Net Sales of

38/147

all Products Targeting any given Selected Target (for clarity, all Annual Net Sales of Products Targeting a Selected Tar get shall be aggregated for purpose of calculating the tiers):


Annual Net Sales			Royalty Rate for Product(s) Targeting a Selected Target
Portion of worldwide Annual Net Sales less than or equal to \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			n%
Portion of worldwide Annual Net Sales in excess of \|\|\|\|\|\|\|\|\|\|\|\| and less than or equal to \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			n%
Portion of worldwide Annual Net Sales in excess of \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			n%

7.6.2 Royalty Term

Sanofi’s obligation to pay royalties to Innate on Annual Net Sales of a Product shall commence, on a country-per-country and Product-by-Product basis upon the First Commercial Sale of a Product in a country and expire on a Product-by-Product and country-per-country basis, upon the latest of:

(a) ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

(b) the last to expire Valid Claim of a ||||||||||||||||||||||||||||||||||||||||||||||| in such country which would, if Sanofi did not own such Patent Right or have an exclusive (sub)license under it. be infringed by the sale of such Product: and

(the “Royalty Term”).

Upon the expiration of the Royalty Tenn for all Product(s) with respect to a Selected Target in a particular country, the licenses granted to Sanofi under Section 2.2.1 shall automatically and without further action on the part of Innate or Sanofi become irrevocable, fully paid-up and perpetual with respect to such Products in such country and Net Sales of such Products in such country shall be excluded from the calculation of Annual Net Sales (including for purposes of applying thresholds and ceilings).

7.6.3 Royalty Reductions

(a) Third-Party Intellectual Property Rights

Innate shall be solely responsible for all liabilities and obligations associated with its licensing or other agreements related to Third Party Intellectual Property Rights which are necessary for Innate to gr ant the licenses and other rights granted to Sanofi under the Innate IP in this Agreement and which licensing or other agreements related to Thu d Party Intellectual Property Rights are in existence as of the Effective Date.

39/147

Sanofi shall be solely responsible for all liabilities and obligations associated with its licensing or other agreements related to Third Party Intellectual Property Rights which are necessary for Sanofi to grant the licenses and other rights granted to Innate under the Sanofi IP in this Agreement and which licensing or other agreements related to Third Party Intellectual Property Rights are in existence as of the Effective Date.

After the Effective Date, Sanofi, at its sole expense, shall negotiate and pay all license or acquisition costs of any Third-Party Intellectual Property Rights, including upfront payments and/or royalties (“Third-Party IP Payments”) that are necessary in order for Sanofi to exercise Sanofi’s rights hereunder to research, Develop, Manufacture, and Commercialize any Product.

Without prejudice to any other legal remedy available to either Party, Sanofi shall be authorized to deduct from royalty payments due to Innate pursuant to Section 7.6 with respect to Net Sales of a Product in any given country, |||||||||| of any Third-Party IP Payments paid by Sanofi in consideration of a license to use a granted and unexpired composition of matter, method of use or a method of manufacturing (to the extent such method of manufacturing is used only for the Product) patent in such country covering a Product, provided that the amounts paid by Sanofi to Innate in such country shall not be reduced by more than (i)|||||||||| of the amount set forth in the table of Section 7.6.1 (the “Third-Party Intellectual Property Royalty Floor”) in the absence of any other royalty reduction event pursuant to this Section 7.6.3 or (ii) the Royalty Floor (as defined in Section 7.6.3(e)) if other royalty reduction events have taken place pursuant to this Section 7.6.3. In the event Sanofi does not recoup |||||||||||||||||||||||||||||||||||||||| of such Third Party IP Payments, due to the application of the Third-Party Intellectual Property Royalty Floor or the Royalty Floor, as applicable, in a given period or otherwise, it may carry over and deduct the remaining amounts in future periods until it has deducted the |||||||||||||||||||||||||||||||||||||||| of such Third Party IP Payments.

(b) Generic Competition

If, at any time, in a particular country in the Territory, (i) a Generic Product receives Regulatory Approval in such country and is introduced for commercial sale into such country, and (ii) the Net Sales of the relevant Product sold in such country in any given Calendar Quarter (including the first Calendar Quarter in which the Generic Product is sold in such country) decrease by more than |||||||||||||||||||||||||||||||||||||||||||||||||| but no more than |||||||||||||||||||||||||||||| compared to the average Net Sales of the two Calendar Quarters immediately preceding the first Calendar Quarter in which the Generic Product is sold, then, the royalties that would otherwise have been payable on Net Sales of such Product in such country under this Agreement shall be reduced by |||||||||||||||||||||||||||||||||||||||| as from the first Calendar Quarter in which that Section applies and thereafter for so long as the Net Sales of the relevant Product sold in a given Calendar Quarter are at least |||||||||||||||||||||||||||||||||||||||||||||||||| but no more than |||||||||||||||||||||||||||||||||||||||| less than the average Net Sales of such Product sold in the two Calendar Quarters immediately preceding the first Calendar Quarter in which the Generic Product is sold. If, at any time, in a particular country in the Territory, (i) a Generic Product receives Regulatory Approval in such country and is introduced for commercial sale into such country, and (ii) the Net Sales of the relevant Product sold in such country in any given Calendar Quarter (including the first Calendar Quarter in which the Generic Product is sold in such country) decrease by more than |||||||||||||||||||||||||||||||||||||||| compared to the average Net Sales of the two Calendar Quarters immediately preceding the first Calendar Quarter in which the Generic Product is sold, then, the royalties that would otherwise have been payable on Net Sales of such Product in such country under this Agreement shall be reduced by |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| as from the first Calendar

40/147

Quarter in which that Section applies and thereafter for so long as the Net Sales of the relevant Product sold in a given Calendar Quarter are at least |||||||||||||||||||||||||||||||||||||||| less than the average Net Sales of such Product sold in the two Calendar Quarters immediately preceding the first Calendar Quarter in which the Generic Product is sold.

The calculation of the royalty reduction under this Section 7.6.3(b) shall be conducted separately for each Product in each country.

If Applicable Laws or a court or a governmental agency of competent jurisdiction requires Sanofi or any of its Affiliates or its or their Sublicensees to grant a compulsory license to a Third Party permitting such Third Party to make and sell a Product in a country in the Territory (a “Compulsory License”), and the royalty rate for royalties payable to Sanofi, its Affiliates or its or their Sanofi Licensees or Sublicensees on Net Sales (which term for the purpose of this Section 7.6.3 shall apply mutatis mutandis to sales by such grantee) of Products by or on behalf of such grantee of the Compulsory License is less than the royalty rate for royalties on Net Sales due to Innate pursuant to this Agreement in such country, then the royalty rate applicable to Net Sales for royalties due to Innate in such country shall be reduced to be equal to |||||||||||||||||||||||||||||||||||||||| of the royalty rate for royalties payable by the grantee of the

Compulsory License. If Sanofi or its Affiliates receives any compensation (other than royalty payments) for the Compulsory License from the grantee of the Compulsory License, then Sanofi shall pay Innate |||||||||||||||||||||||||||||||||||||||||||||||||| of such compensation (but such compensation shall otherwise be disregarded for the purpose of applying thresholds and ceilings). If Sanofi, its Affiliates, or Sublicensees learn that a Third Party is seeking a Compulsory License in any country in the Territory, Sanofi shall use Commercially Reasonable Efforts to oppose the granting of such Compulsory License. The royalty rate reduction set forth herein shall be effective as from the first Calendar Quarter in which this Section 7.6.3 (c) applies and thereafter for so long as this Section 7.6.3 (c) applies. The calculations of the royalty rate reduction under this Section 7.6.3 (c) shall be conducted separately for each Product in each country.

(d) Order of Reductions

Any reductions set forth in Sections 7.6.3 (a) to (c) shall be cumulative and shall be applied in the order in which the event triggering such reduction occurs.

(e) Royalty Floor

During the Royalty Term in any given country, the reductions set forth in Sections 7.6.3(a) to (c) shall not reduce the royalties payable by Sanofi to Innate in such country by more than |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| of the amount set forth in the table of Section 7.6.1 (the “Royalty Floor”).

7.6.4 Royalty Payments and Reports

The royalties payable under this Section 7.6 shall be calculated quarterly as of the last day of March, June, September and December respectively for the Calendar Quarter ending on that date. Sanofi shall deliver to Innate a report summarizing the Net Sales of Products, on Selected Target per Selected Target

41/147

basis during each Calendar Quarter following the First Commercial Sale of a Product in the Territory. Such report shall be delivered within |||||||||||||||||||||||||||||||||||||||| following the end of each Calendar Quarter for which royalties are due from Sanofi. Innate shall invoice Sanofi for the corresponding Royalty Payments at any time within |||||||||||||||||||||||||||||| of the receipt of such report and Sanofi pay such invoice within |||||||||||||||||||||||||||||||||||||||| of its receipt.

7.7 Payments by Innate to Sanofi upon the exercise by Innate of its Reversion Rights

If Innate delivers to Sanofi an Election Notice for a Discontinued Product pursuant to Section 12.3.1(c) the payments set forth in Schedule 7.7, which vary upon the development status of such Discontinued Product at the time of the exercise of its Reversion Rights by Innate, shall be due by Innate to Sanofi as long as any Discontinued Product is Commercialized or otherwise Exploited, by Innate, its Affiliate or its Sublicensee in any country in the Territory.

7.8�� Taxes and Withholding

The royalties, milestones and other amounts payable by Sanofi to Innate pursuant to this Article 7 (“Payments”) shall not be reduced on account of taxes unless required by Applicable Laws. Sanofi shall deduct or withhold from the Payments any taxes that it is required by Applicable Laws to deduct or withhold. Notwithstanding the foregoing, if Innate is entitled (whether under any applicable tax treaty or otherwise under Applicable Laws) to a reduction in the rate of, or the elimination of, withholding tax, it may deliver to Sanofi or the appropriate governmental authority (with the assistance of Sanofi to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Sanofi of its obligation to withhold tax, and Sanofi shall apply the reduced rate of withholding, or dispense with withholding, as the case may be. If, in accordance with the foregoing, Sanofi withholds any tax, it shall make timely payment to the competent tax Authority for the withheld tax, in accordance with Applicable Laws, and send to Innate proof of such payment within |||||||||||||||||||||||||||||||||||||||| following that payment. Sanofi agrees to make reasonable and lawful efforts to minimize such taxes to Innate. Sanofi shall cooperate with Innate as reasonably requested in any claim for refund or application to any tax authority. If Sanofi intends to withhold tax from any Payment, Sanofi shall inform Innate reasonably in advance of making such Payment to permit Innate an opportunity to provide any forms or information or obtain any approval from such tax authority as may be available to reduce or eliminate such withholding. In the event that (i) Sanofi assigns or otherwise transfers its rights or obligations under this Agreement to one of its Affiliates that is not resident for taxes purposes in France, without obtaining the prior written consent of Innate (a “Unilateral Assignment”), (ii) such Unilateral Assignment results in the net Payment after tax, accounting for any foreign tax credits that reduce the cost of withholding tax, received by Innate under this Agreement being lower than it would have been but for the Unilateral Assignment because of the imposition of additional withholding taxes and (iii) Innate is resident in France for tax purposes, then Sanofi procures that all Payments thereafter (for as long as all of (i) through (iii) apply) made hereunder by the assignee or the transferee to Innate shall be increased such that net Payment after taxes received by Innate is equivalent to the amount to which Innate would have been entitled but for the Unilateral Assignment, provided that Innate shall be under a duty to take all reasonable steps to mitigate the effect of the Unilateral Assignment (for example by claiming double taxation relief with advance written notice to Sanofi), and Sanofi procures that the assignee or the transferee shall cooperate with Innate with respect to any documentation required by the appropriate governmental authority or

42/147

reasonably requested by Innate to secure a reduction of the rate of, or the elimination of, the applicable taxes withheld.

7.9 Payment Terms

7.9.1 Invoicing

Innate shall invoice Sanofi for all payments due and payable to it hereunder and, except as otherwise provided in this Agreement, each such invoice shall be paid within |||||||||||||||||||||||||||||||||||||||| after the receipt of the applicable invoice.

All invoices provided by under this Agreement shall specify the contractual event for which payment is due, as well as payment instructions, and shall be sent by email to Sanofi at the following address : Sanofi-Invoices-US@sanofi-ssc.com

7.9.2 Interest on Late Payments

Any uncontested amount required to be paid by Sanofi under this Agreement which is not paid on the date due shall bear interest calculated and accrued at the annual rate Euro Interbank Offered Rate (EURIBOR) 3 months plus two percent (2%) from the date of payment was due. Such interest shall be accrued daily.

7.9.3 Currency

Unless indicated otherwise, any and all payment amounts referred to in this Agreement shall be in euros. Except as otherwise specifically provided in this Agreement, any and all payments due from one Party to the other pursuant to this Agreement shall be made in euros by wire transfer of immediately available funds to such account or accounts and in accordance with such payment instructions as are provided by the payee from time to time.

7.9.4 Currency Conversion

In the event that any amounts in respect of which payments or reports from Sanofi to Innate are owing or due hereunder are denominated in a currency other than euros, such amounts shall be converted into euros at the rate of exchange used by such Party for its external financial reporting.

7.9.5 Financial Audits

(a) Innate shall have the right to examine and audit Sanofi’s relevant books and records to verify the accuracy of any reports and and/or payments prepared and/or delivered by such Party pursuant to this Agreement (each an “Audit”). Any such Audit shall be on at least |||||||||||||||||||||||||||||| prior written notice and Innate’s rights to perform an Audit shall be limited to one (1) Audit in any Calendar Year and shall be limited to the pertinent books and records for any Calendar Year ending not more than |||||||||||||||||||||||||||||||||||||||||||||||||| before the date of the request.

43/147

(b) The Audit shall be performed at Innate’s sole expense by an independent certified public accounting firm of internationally recognized standing that is selected by Innate and reasonably acceptable to Sanofi. The accounting firm may be required to enter into a reasonable and customary confidentiality agreement with Sanofi to protect the confidentiality of its books and records. Sanofi shall make the relevant books and records reasonably available during normal business hours for examination by the accounting firm. Except as may otherwise be agreed, the accounting firm shall be provided access to such books and records at Sanofi’s and/or its Affiliates’ facilities where such books and records are normally kept. Upon completion of the audit, the accounting firm shall provide both Parties a written report disclosing whether or not the relevant reports and/or payments are correct, and the specific details concerning any discrepancies. The accounting firm shall not provide Innate with any additional information or access to Sanofi’s confidential information.

(c) If an Audit concludes as a result of such Audit that any underpayments or overpayments were made by a Party, then any underpaid amounts shall be paid or overpaid amounts reimbursed to such Party within |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| of the date of invoicing. In the event that the total amount of any underpayments by Sanofi to Innate for the audited period exceeds |||||||||||||||||||||||||||||||||||||||||||||||||| the aggregate total amount that was properly due and payable to Innate for such period, then Sanofi shall also reimburse Innate for the documented, reasonable out-of-pocket expenses incurred in conducting the Audit, except to the extent that such underpayment was due to any inaccurate or incomplete information provided to Sanofi by Innate.

ARTICLE 8. INTELLECTUAL PROPERTY RIGHTS

8.1 Intellectual Property Ownership

8.1.1 lunate IP

Subject to the licenses granted by Innate to Sanofi pursuant to Article 2, as between the Parties Innate shall own and retain all rights, title and interest in and to the Innate IP.

8.1.2 Sanofi IP

Subject to the licenses granted by Sanofi to Innate pursuant to Article 2, as between the Parties Sanofi shall own and retain all rights, title and interest in and to the Sanofi IP.

8.1.3 Collaboration IP

(a) Subject to the licenses granted pursuant to Article 2, the Parties agree that any and all Collaboration IP shall be jointly and equally owned by the Parties; provided however, that such joint ownership interests and the Parties’ respective rights and obligations with respect to the Collaboration IP shall be subject to the terms of this Agreement. To the extent any of the Collaboration IP has been solely invented and/or is solely owned by a Party, such Party hereby assigns to the other Party a joint ownership right therein.

44/147

(c) Sanofi shall have the exclusive right (but not the obligation), at its sole discretion, to decide which applicant should be listed (named) first amongst the co-owned Collaboration IP.

8.1.4 Third Party’ Intellectual Property’ in connection with a merger or an acquisition

Subject to Section 2.2.4. if. after the Effective Date, a Party enters into a transaction as a result of which such Party has become an Affiliate of a Thud Party that is a Healthcare Company or has sold, leased, or otherwise transferred (in one or more transactions) to a Healthcare Company, all or substantially all of such party’s assets or that portion of such Party’s assets relating to this Collaboration, no Intellectual Property Controlled by such Healthcare Company or any of its affiliates prior to such transaction or developed or acquired by them after such transaction independently of the Innate IP. Sanofi IP or the Collaboration IP, shall be deemed to be Controlled for purposes of this Agreement by the Party which is the subject to such transaction solely as a result of such transaction, unless such Intellectual Property is actually used by such Party in performing its responsibilities pursuant to this Agreement.

8.1.5 Assignment of Inventions

Each Party shall, and shall cause its Affiliates to. require that any and all of its employees, agents, consultants and contractors performing any activities under or contemplated by this Agreement are obligated in writing to assign all of his/her rights, title and interests in and to any inventions to the Party for which such employee, agent, consultant or contractor is providing its services. To the extent that Applicable Laws in the relevant jurisdiction expressly require that compensation be provided to the individual inventor(s) solely as a result of his/her contribution as an inventor of a given invention each Party shall be responsible for providing such compensation to its inventors.

45/147

All determinations of inventorship under this Agreement shall be made in accordance with the Applicable Laws of the United States as in effect at the relevant time of determination.

8.2 Filing, Prosecution and Maintenance of Patent Rights

8.2.1 Innate Patents

Subject to Section 8.2.3, Innate shall have the exclusive right (but not the obligation) at its sole cost and discretion, to control the preparation, filing, prosecution, maintenance and enforcement of the Innate Patents throughout the Territory. Innate shall promptly submit draft application(s) for the Innate Patents that disclose and claim an Innate Antibody or an Innate Format to Sanofi, and provide Sanofi with copies of any material communications received from or filed with any patent office(s) with respect to such application(s) for Innate Patents that disclose and claim an Innate Antibody or an Innate Format to Sanofi, to the extent possible ||||||||||||||||||||||||||||||||||||||||, in advance of filing and consider in good faith the incorporation of reasonable comments by Sanofi.

8.2.2 Sanofi IP

Sanofi shall have the exclusive right (but not the obligation) at its sole cost and discretion to control the preparation, filing, prosecution, maintenance and enforcement of the Patent Rights within the Sanofi IP throughout the Territory.

8.2.3 Jointly Prosecuted Patents

(a) On a Selected Target per Selected Target basis, Sanofi shall have the first right (but not the obligation), at its sole expense and sole discretion, in consultation with Innate pursuant to subclause (b), to control the preparation, filing, prosecution, maintenance and enforcement of (i) (A) the Innate Target Patent listed in Schedule 3.1.1(a), and (B) all Innate Patents that claim the Pre-Hits, Hits, Leads, Pre-Development Candidates, Candidates, or Back-ups (the “Innate Target Patents”); and (ii) all Collaboration Patents for such Selected Target ((i) and (ii) the “Jointly Prosecuted Patents”), throughout the Territory, and any substantive response, amendment, paper or other correspondence related thereto with the relevant patent authority; provided however that Sanofi shall not without Innate’s prior written consent disclose in any patent or other application any Innate Format or Innate Antibody other than the Innate Format and Innate Antibody incorporated in a Pre-Hit, Hit, Lead, Pre-Development Candidate, Candidate, or Back-up, or any Innate Technology or any Innate Materials.

(b) Sanofi shall (i) promptly submit draft application(s) of Jointly Prosecuted Patents to Innate reasonably, and to the extent possible ||||||||||||||||||||||||||||||| in advance of filing and consider in good faith the incorporation of reasonable comments by Innate thereon including any request by Innate to delete Innate’s Confidential Information from the Jointly Prosecuted Patent applications; (ii) promptly provide Innate with a copy of all documents filed in connection with any Jointly Prosecuted Patent application once filed; (iii) promptly provide Innate with copies of any material communications received from or filed with any patent office(s) with respect to such filing; (iv) promptly notify Innate of any interference, opposition, reexamination request, nullity proceeding, appeal or other interparty action; and (v) provide

46/147

Innate with written notice as early as possible prior to abandoning the prosecution or maintenance of any Jointly Prosecuted Patents.

(c) Innate shall cooperate with Sanofi and cause its employees, agents or consultants, at its expense, to execute such documents and to take such other actions as reasonably necessary or appropriate to enable Sanofi to prepare, file, prosecute and maintain such Jointly Prosecuted Patents.

(d) In the event that Sanofi provides Innate with the written notice described in clause (v) of paragraph (b) of this Section 8.2.3. prior to not exercising its first right to prepare, file, prosecute or maintain, deciding to abandon or allow to lapse, or otherwise determining not to continue the prosecution or maintenance of any Jointly Prosecuted Patent in any country or region in the Territory for other than a Strategic Reason, then Innate shall have the option, exercisable by delivery of a written notice thereof within thirty (30) days thereafter, to assume the right (but not the obligation), at its sole expense and sole discretion, to control the preparation, filing, prosecution and maintenance of such Jointly Prosecuted Patent.

(e) ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

(f) |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

47/147

8.2.4 Post-Grant Proceedings initiated by a Party

(a) Innate shall not have the right to file any Post Grant Proceeding regarding any Jointly Prosecuted Patent in the Territory.

(b) If Sanofi intends to file a Post Grant Proceeding with respect to a Jointly Prosecuted Patent:

(i) Sanofi shall promptly notify Innate in writing;

(ii) Upon receipt of such notice, the Parties shall engage in good faith consultations about the merits of such Post Grant Proceeding; provided, however, that Sanofi shall have final decision authority with respect to whether such file such proceeding.

(c) If such a Post Grant Proceeding is filed by Sanofi. Innate shall not file any substantive response, amendment, paper or other correspondence with the relevant patent authority, and. notwithstanding the provisions of Section 8.2.3(b), Sanofi shall provide to Innate:

(i) a copy of any action, communication, letter, or other correspondence issued by the relevant patent authority within at least ten (10) days of receipt thereof;

(ii) a copy of any response, amendment, paper, or other correspondence to be filed with the relevant patent authority reasonably in advance of filing and consider in good faith the incorporation of reasonable comments by Innate thereon; and

(iii) a copy of any response, amendment, paper, or other correspondence as filed with the relevant patent authority no more than ten (10) days after Sanofi receives confirmation from the relevant patent authority that the response, amendment, paper, or other correspondence has been filed.

48/147

8.2.5 Patent Extensions

Sanofi shall be solely responsible to make the determination as to whether to seek patent term extensions, including supplementary protection certificates (national supplementary protection certificates before national authorities or Unitary Supplementary Protection Certificates) and any other extensions that are now or become available in the future regarding the Patent Rights within the Sanofi IP, and Jointly Prosecuted Patents, with respect to any Product in each country in the Territory in order to secure or improve Patent Rights protection for such Product under Applicable Laws. Innate shall, and shall cause its Affiliates to, at Sanofi’s request and sole cost and expense (as to reasonable and properly incurred out-of-pocket expenses only), assist and cooperate with Sanofi in any such filing or application.

8.2.6 Unified Patent Court; Unitary Patents of Jointly Prosecuted Patents

(a) Unified Patent Court: Opt-Out and Withdrawal of Opt-out.

Notwithstanding anything to the contrary herein, Sanofi shall have the following rights with respect to the Jointly Prosecuted Patents:

(i) regarding the co-owned Jointly Prosecuted Patents, Sanofi shall have the sole right (but not the obligation), at its sole expense and sole discretion, to (A) file an application to Opt Out any European Patent from the exclusive competence of the Unified Patent Court or (B) lodge an application to Withdraw an Opt-Out with respect to any European Patent from the exclusive competence of the Unified Patent Court, in accordance with Applicable Laws (including Article 83 of Unified Patent Court Agreement and Rule 5 of the Rules of Procedure of the Unified Patent Court). Innate shall provide on request all evidence or signed document needed to perform a valid Opt-Out, or a valid Withdrawal of an Opt-Out;

(ii) regarding the Jointly Prosecuted patents owned by Innate, Innate shall, at Sanofi’s sole discretion, cost and expense, as soon as reasonably practicable after a request by Sanofi, and within ||||||||||||||||||||||| after the request, (A) file an application to Opt Out any European Patent specified by Sanofi from the exclusive competence of the Unified Patent Court, pay any prescribed fee and take any action as may be necessary or useful to secure the Opt-Out, or (B) lodge an application to Withdraw an Opt-Out with respect to any European Patent specified by Sanofi from the exclusive competence of the Unified Patent Court, pay any prescribed fee and take any action as may be necessary or useful to secure the Withdrawal, in accordance with Applicable Laws (including Article 83 of Unified Patent Court Agreement and Rule 5 of the Rules of Procedure of the Unified Patent Court). Sanofi shall provide on request all evidence or signed document needed to perform a valid Opt-Out, or a valid Withdrawal of an Opt-Out.

49/147

(b) Unitary Patents: Request for Unitary Effect.

(i) - Sanofi shall have the sole right (but not the obligation), at its sole expense, to file a request for Unitary Effect for any European granted patent within the co-owned Jointly Prosecuted Patents. Innate shall provide on request all evidence or signed document needed to perform a valid request for Unitary Effect;

(ii) - Innate shall, at Sanofi’s sole cost and expense, as soon as reasonably practicable after a request by Sanofi (A) file a request for Unitary Effect for any European granted patent specified by Sanofi within the Jointly Prosecuted patents owned by Innate, and (B) take such other actions as may be necessary or useful to secure the request for Unitary Effect of such European granted patent including filing any required translation referred to in Article 6.1. of Regulation (EU) No. 1260/2012.

Capitalized terms in Section 8.2.5 and in this Section 8.2.6 shall have the meaning given to such terms in the Rules of Procedure of the Unified Patent Court as adopted by decision of the Administrative Committee on 8 July 2022 and established by the Agreement on a Unified Patent Court of 19 February 2013 (OJ C 175, 20.6.2013, p. 1) (including any subsequent amendments).

8.3 Enforcement of Patent Rights

8.3.1 Notification of Infringement

If either Party learns of (a) any infringement or misappropriation or threatened infringement or misappropriation by a Third Party (including by filing or threatening to file, an abbreviated biologics license application under Section 351 (k) of the Public Health Services Act or any equivalent legislation of the European Union or any country within the Territory), or (b) any declaration of non-infringement with respect to the Innate Patents, the Patent Rights within the Sanofi IP or the Collaboration Patents, such Party shall promptly notify the other Party, and in any case in no more than ||||||||||||||||||||||||||||||| after such Party becomes aware, for instance after being notified in writing, of any declaration of non-infringement, and shall provide the other Party with any available evidence of such infringement or misappropriation.

8.3.2 Enforcement of Jointly Prosecuted Patents

(a) With respect to the Jointly Prosecuted Patents, Sanofi shall have the first right, but not the obligation, at its own expense and through counsel of its choosing, to take any action it deems appropriate including commencing any legal action, claim or proceedings, for instance to defend against a declaration of noninfringement, to stop such infringing activities or misappropriation by such Third Party in any part of the Territory.

(b) Upon request by Sanofi, Innate shall reasonably assist Sanofi in such legal action, claim or proceedings by (i) giving Sanofi all reasonable information in its possession in connection with Sanofi’s legal action, claim or proceeding, including allowing Sanofi access to Innate’s files and documents and to Innate’s personnel who may have possession of relevant information, (ii) to the extent necessary by joining in such legal action as a party, executing

50/147

appropriate legal documents, and (iii) seeming the cooperation of inventors or other witnesses for the benefit of the Parties and Sanofi shall reimburse Innate for reasonable costs incurred with respect to such joinder.

(c) In the event that Sanofi fails, within |||||||||||||||||||| following notice of such infringement, or earlier notifies Innate in writing of its intent not to commence any legal action, claim, or proceeding against any infringement or misappropriation of any Jointly Prosecuted Patents that is likely to have a material adverse effect on the sale of a Product in the Territory then, unless Sanofi provides Innate with a commercially reasonable basis in writing for not taking such steps. Innate shall have the right, but not the obligation, to do so at Innate’s sole cost and expense; provided, however, that if Sanofi has commenced negotiations with an alleged infringer for discontinuance of such infringement within such |||||||||||||||||||| Sanofi shall have an additional |||||||||||||||||||||| to conclude its negotiations before Innate may commence any legal action to stop such infringing activities or misappropriation by such Third Party in any part of the Territory.

8.3.3 Enforcement of Patent Rights w ithin the Sanofi IP

With respect to Patent Rights within the Sanofi IP. Sanofi shall have the sole right (unless otherwise expressly agreed between the Parties), but not the obligation, at its own expense and through counsel of its choosing, to take any action it deems appropriate including commencing any legal action, claim or proceedings to stop such infringing activities or misappropriation by such Third Party in any part of the Territory. Upon request by Sanofi. Innate shall reasonably assist Sanofi in such legal action, claim or proceedings subject to Sanofi’s reimbursement on a Quarterly basis of any reasonable out-of-pocket costs and expenses incurred by Innate.

8.3.4 Enforcement of Innate Patents

(a) With respect to Innate Patents which are not Jointly Prosecuted Patents. Innate shall have the sole right, but not the obligation, at its own expense and through counsel of its choosing, to take any action it deems appropriate including commencing any legal action, claim or proceedings to stop such infringing activities or misappropriation by such Third Party in any part of the Territory.

(b) Notwithstanding (a), with respect to Innate Patents which are not Jointly Prosecuted Patents, if (i) the infringing activities or misappropriation relates to a competing Multispecific Antibody Targeting a Selected Target whose Activating Receptor ABD and Selected Target ABD have the same CDR amino acid sequences as those of a Candidate and (ii) there is no Jointly Prosecuted Patent or Sanofi Patent available to enforce against the infringing activities of (i), then Sanofi shall have the right, at its own expense and through counsel of its choosing, to commence a legal action, claim or proceedings to stop such infringing activities or misappropriation by such Third Party in any part of the Territory. Upon request by Sanofi. Innate shall reasonably assist Sanofi in such legal action, claim or proceedings and Sanofi’s costs.

(c) Unless mutually agreed otherwise by the Parties, Innate.|||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

51/147

8.3.5 Settlement with a Third Party

The Party that controls the prosecution of a claim, action or proceeding with respect to any Patent Right shall also have the right to control settlement of such claim; provided, however, that no settlement of such action, claim, or proceeding, which materially restricts the scope, or materially affects the enforceability or validity of any Patent Rights controlled by a Party may be entered into without the written consent of such other Party, not to be unreasonably withheld or delayed.

8.3.6 Damages

In the event that either Party recovers any damages or other sums in such action, suit or proceeding brought under Sections 8.3.2 in relation to Patent Rights, or in settlement thereof, then such damages or other sums recovered shall first be applied to all out of pocket costs and expenses incurred by the Parties in connection therewith, including, attorneys’ fees and other litigation costs. If such recovery is insufficient to cover all such costs and expenses of both Parties, the shortfall shall be shared on a pro rata basis in proportion to the total of such costs and expenses incurred by each Party. If, after such reimbursement, any funds shall remain from such damages or other sums recovered, such funds shall be shared by the Parties as follows:

(a) |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

(b) |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

8.4 Third Party Infringement Defense

In the event that a Third Party institutes a Patent Right infringement suit against Innate or Sanofi during the Term, alleging that the Exploitation of a Product in accordance with this Agreement infringes the Intellectual Property Rights of such Third Party, then Sanofi shall have the first right, but not the obligation, at its sole cost and expense, to assume direction and control of the defense of claims arising therefrom including the right to settle such claims at its sole discretion, provided that Sanofi shall not settle or otherwise compromise any such claims without the written consent of Innate, not to be unreasonably withheld or delayed. Innate shall assist and cooperate in connection with the defense of such suit upon the reasonable request of Sanofi, |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

52/147

8.5 Invalidity or Unenforceability Defense

(a) If a Third Party asserts, as a defense or as a counterclaim in any infringement action under Section 8.3.2 (Enforcement of Jointly Prosecuted Patents), or in a declaratory judgment action or similar action or claim filed by such Third Party within the Territory, that any Jointly Prosecuted Patent is invalid or unenforceable, then the Party pursuing such infringement action, or the Party first obtaining knowledge of such declaratory judgment action, as the case may be, shall promptly, and in no more than |||||||||||||||||||||||||| after such Party becomes aware of the defense, counterclaim or any other action challenging the validity or enforceability of a Jointly Prosecuted Patent, give written notice to the other Party.

(b) Sanofi shall have the first right, but not the obligation, at its sole cost and expense, and through counsel of its choosing, to assume direction and control of the defense against an invalidity, revocation or enforceability action. In addition to Sanofi having the discretion to defend against an action as mentioned above, Sanofi shall have the sole right to decide, at its own discretion, how to conduct the litigation, including the choice of the Court if such a choice exists (for example litigation before the UPC or a national court, location of the Court in both cases), the language of the proceedings, and any other choice related to the litigation.

(c) Innate shall execute all reasonable, necessary and proper documents and take such actions as shall be appropriate to allow Sanofi to institute and prosecute infringement actions under this Section 8.5.

8.6 Third Party Post Grant Proceedings

8.6.1 If either Party learns that a Third Party has filed a Post Grant Proceeding regarding any Jointly Prosecuted Patent, the Party who first learns of such Post Grant Proceeding shall notify the other Party in writing no later than ||||||||||||||||||||||||| after the Party learns of the filing. Sanofi shall have the exclusive right (but not the obligation), at its sole expense and sole discretion, to control all Post Grant Proceedings with respect to Jointly Prosecuted Patents, on behalf of the Parties.

8.6.2 Once such a Post Grant Proceeding has commenced, Sanofi shall provide to Innate:

(a) a copy of any proposed response, amendment, paper, or other correspondence to be filed with the relevant patent authority reasonably in advance of filing and consider in good faith the incorporation of reasonable comments by Innate thereon; and

(b) a copy of any response, amendment, paper, or other correspondence as filed on behalf of Sanofi and Innate jointly with the relevant patent authority no more than ||||||||||||||||||||||||||| after Sanofi receives confirmation from the relevant patent authority that the response, amendment, paper, or other correspondence has been filed; and

(c) a copy of any action, communication, letter, or other correspondence issued by the relevant patent authority in connection with such Post Grant Proceeding within at least |||||||||||||||||||||||||| of receipt thereof.

53/147

8.7 CREATE Act

Notwithstanding anything to the contrary in this Article 8 neither Party shall have the right to make an election under the Cooperative Research and Technology Enhancement Act of 2004. 35 U.S.C. 103(c)(2)-(c)(3) (the “CREATE Act”) when exercising its rights under this Section 8 without the prior written consent of the other Party. With respect to any such permitted election, the Parties shall coordinate their activities with respect to any submissions, filings, or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a “joint research agreement” as defined in the CREATE Act.

ARTICLE 9. REPRESENTATIONS AND WARRANTIES - CLOSING CONDITIONS

9.1 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

54/147

9.2 Representations and Warranties of Innate

9.2.1 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

55/147

9.3 Representations and Warranties of Sanofi

9.3.1 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

9.4 DISCLAIMER

EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT. EACH PARTY MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND. EITHER EXPRESS OR IMPLIED. INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF SAFETY. EFFICACY. MERCHANTABILITY. SATISFACTORY QUALITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY MATTER ARISING IN CONNECTION WITH THIS AGREEMENT (INCLUDING ANY ACTIVITIES CONDUCTED HEREUNDER), OR THE MATERIALS OR ANY PRODUCTS.

56/147

9.5 Closing Conditions.

The obligations of each Party to consummate the Contemplated Transactions is subject to the fulfillment, or, to the extent permitted by Applicable Law, waiver by such Party, of each of the following conditions (collectively, the “Closing Conditions”):

9.5.1 Representations and Warranties.

The representations and warranties of the other Party contained in this Agreement (a) that are not qualified by materiality, material adverse effect, substantial compliance or similar materiality qualifier will be true and correct in all material respects both when made and at the closing with the same force and effect as if made on the Effective Date, and (b) that are qualified by materiality, material adverse effect, substantial compliance or similar materiality qualifier will be true and correct in all respects both when made and at the closing with the same force and effect as if made on the Effective Date, except in respect of both (a) and (b) as set forth in a disclosure schedule provided to a Party making the representation or warranty prior to the Effective Date.

9.5.2 Antitrust Filing.

All actions by (including any authorization, consent or approval), in respect of (including notice to), or filings with, any governmental authority or other Person that are required to be obtained pursuant to Section 13.2 (Filings) to consummate the Contemplated Transactions (including any HSR/Antitrust Filing) will have been obtained or made, in a manner reasonably satisfactory in form and substance to such Party, and no such authorization, consent or approval will have been revoked.

ARTICLE 10. NONDISCLOSURE OF CONFIDENTIAL INFORMATION

10.1 Nondisclosure

Each Party agrees that, during the Term and for a period of ten (10) years thereafter, a Party (the “Receiving Party”) receiving Confidential Information of the other Party (the “Disclosing Party”) pursuant to or in connection with this Agreement shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own proprietary industrial information of similar kind and value, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this clause (d) shall not create or imply any rights or licenses not expressly granted under Article 2 hereof).

10.2 Exceptions

The obligations in Section 10.1 shall not apply with respect to any information including any portion of Confidential Information that:

(a) is publicly disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party hereunder; or

(b) was known to the Receiving Party or any of its Affiliates, without any

57/147

obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party, and such prior knowledge can be properly documented by the Receiving Party; or

(c) is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use; or

(d) is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is disclosed to the Receiving Party without the fault or cause of the Receiving Party; or

(e) is independently developed by employees or contractors of the Receiving Party or any of its Affiliates without the aid, application or use of Confidential Information of the Disclosing Party, and such independent development can be properly documented by the Receiving Party.

10.3 Authorized Disclosure

The Receiving Party may disclose Confidential Information belonging to the Disclosing Party only to the extent that such disclosure is reasonably necessary in the following instances:

(a) unless otherwise expressly provided in this Agreement, to any relevant patent office in preparing, filing, prosecuting and maintaining patents in accordance with the provisions of Article 8;

(b) to Regulatory Authorities in order (i) to obtain authorizations to conduct clinical trials or post-approval studies in relation to any Candidate or Products, or (ii) to file, obtain and maintain Regulatory Approvals in respect of Products, or (iii) to Develop, Commercialize or Manufacture any Product, in each case in accordance with this Agreement;

(c) in prosecuting or defending litigation or in establishing rights (whether through declaratory actions or other legal proceedings) or enforcing obligations under this Agreement;

(d) subject to Section 10.4, which the Receiving Party is required to disclose by Applicable Laws (including, without limitation, the rules and regulations of the Securities and Exchange Commission, the Autorité des Marchés Financiers, or any national securities exchange) or court order, provided that the Receiving Party immediately notifies (or, if the nature of such legal requirement precludes immediate notification, notifies as soon as possible under the circumstances) the Disclosing Party in writing of such legal requirement or court order and reasonably cooperates with the Disclosing Party, at the Disclosing Party’s sole expense, in the event the Disclosing Party elects to legally contest such disclosure or limit the effect thereof;

(e) solely on a “need to know basis”, to Affiliates, and to its (actual or potential) permitted Third Party Sublicensees, acquirors or assignees under Section 14.4 and subcontractors (and their advisors) and to accountants and legal advisors and each of the Parties’ respective directors, employees, contractors and agents, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use no less restrictive than the obligations set forth

58/147

in this Article 10; provided, however, that the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Section 10.3(e) to treat such Confidential Information as required under this Article 10; and provided further that no such disclosure shall be made to any Person involved in, or any Person whose Affiliates are involved in, the research, Development or Commercialization of any Competing Program.

(f) If and whenever any Confidential Information is disclosed in accordance with this Section 10, such disclosure shall not cause any such information to cease to be Confidential Information, except to the extent that such disclosure results in a public disclosure of such information (otherwise than by breach of this Agreement).

(g) Where reasonably possible and subject to Section 10.4 and other than pursuant to Section 10.3 (e), the Receiving Party shall:

(h) give the Disclosing Party reasonable advance notice of the Receiving Party’s intent to make such disclosure pursuant to this Section 10.3, to the extent practicable; and

(i) provide reasonable co-operation to the Disclosing Party regarding the timing and content of such disclosure and regarding any action which the Disclosing Party may deem appropriate to protect the confidentiality of the information by appropriate legal means.

10.4 Securities Filings

In the event either Party determines that it is required to file with the securities regulators of any country or jurisdiction in the Territory a registration statement or any other required disclosure document which describes any of the terms and conditions of this Agreement, such Party shall promptly notify the other Party of such intention. The Party required to file shall provide such other Party with a copy of relevant portions of the proposed filing not less than |||||||||||||||||||||||||||||||||||||||||||||||||| (or such shorter period of time as may be required, under the circumstances, to comply with Applicable Laws, but in no event less than ||||||||||||||||||||||||||||||||||||||||||||||||||) prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto relating to the terms and conditions of this Agreement. The Party required to file shall use Commercially Reasonable Efforts to obtain confidential treatment of the terms and conditions of this Agreement that such other Party requests be kept confidential and to disclose Confidential Information which it is advised by legal counsel is legally required to be disclosed in order to comply. No such notice shall be required under this Section 10.4 if and to the extent that the specific information contained in the proposed filing has previously been included in any previous filing or disclosure made by either Party hereunder pursuant to this Article 10, or is otherwise approved in advance in writing by the other Party.

10.5 Relationship to Confidentiality Agreement

This Agreement supersedes the confidentiality agreement between the Parties dated September 17, 2021, as amended and extended on October 28, 2021, July 20, 2022 and October 25, 2022 (the “CDA”); provided that any and all “Confidential Information” (as defined in the CDA) that was disclosed or received by the Parties prior to the Effective Date shall be deemed to be Confidential Information that was disclosed pursuant to this Agreement and shall be subject to the terms and conditions of this Agreement.

59/147

10.6 Publication

(a) During the Research Program Period, the Alliance Managers shall be responsible for determining and controlling the timing and content of any publication or public presentation of data, information and/or results relating to the research or Development of any Hits, Leads, Pre-Development Candidates, Candidates, Back-Ups or Products, including any proposed publications in scientific journals and/or presentations at scientific conferences. A Party proposing any such publication or presentation shall provide the other Party’s Alliance Manager with the opportunity to review and approve the content of any proposed abstract, manuscript or presentation which would disclose any data, information or results relating to the research or Development of any Hits, Leads, Pre-Development Candidates, Candidates. Back-Ups or Products by delivering a copy thereof to the other ||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| before its intended submission for publication or presentation. The other Party’s Alliance Manager would then work to promptly consider the matter and shall notify the Party seeking to publish of any specific objections to the disclosure within ||||||||||||||||||||||||||||||||||||||||||||||||||||||| from the receipt of the proposed abstract, manuscript or presentation. The other Party’s Alliance Manager shall have the right to delay a publication or presentation as appropriate to address any relevant concerns. Finally, if the other Party’s Alliance Manager provides no response at all within the aforementioned ||||||||||||||||||||||||||||||||||||||||||||||||||| period, publication shall proceed with no further obligation. Once any such abstract or manuscript is published, the publishing Party will provide the other Party with a copy of the final version of the manuscript or abstract. Any publications by a Party pursuant to this Section 10.6 shall include, as appropriate, an acknowledgement or other form of recognition of the contributions of the other Party.

(b) After the expiry of the Research Program Period. Sanofi shall be solely responsible for determining and controlling the timing and content of any publication or public presentation of data, information and/or results relating to the research or Development of any Hits, Leads, Pre-Development Candidates, Candidates, Back-Ups, or Products, including any proposed publications in scientific journals and/or presentations at scientific conferences, subject to the confidentiality provisions of this Article 10.

(c) For the avoidance of doubt. Innate shall be entitled to disclose to potential partners or investors biological data relating to NKp46 obtained through the Research Program or any subsequent activities of Sanofi in the conduct of its activities pursuant to this Agreement, without disclosing any Selected Target nor the fact that such biological data has been obtained from a collaboration between Innate and Sanofi, and provided such disclosure is made subject to a confidentiality agreement imposing on such potential partners or investors confidentiality obligations which are standard in this type of transaction.

60/147

ARTICLE 11. INDEMNIFICATION

11.1 Indemnification by Sanofi

Sanofi shall indemnify, defend and hold harmless Innate, its Affiliates, and its and their respective officers, directors, employees, and agents, and their respective successors, heirs and assigns and representatives (individually and collectively, the “Innate Indemnified Parties”), from and against any and all Third Party liability, loss, damage, claim, injury, costs or expenses (collectively, “Damages”) that are caused by (whether directly or indirectly):

11.1.1 any failure to timely perform any covenant, obligation or undertaking of Sanofi under this Agreement,

11.1.2 any representation or warranty set forth herein being untrue in any material respect when made by Sanofi, or

11.1.3 any breach or violation of any Applicable Laws by any of Sanofi, its Affiliates, or subcontractors, or any of their respective officers, directors, sales representatives, employees, or agents (collectively, “Sanofi Responsible Parties”) in connection with the activities contemplated by this Agreement, including the research, Development, or Commercialization of Materials or Products, or any negligent act or omission of any Sanofi Responsible Party in connection thereto.

The foregoing notwithstanding, Sanofi shall under no circumstances be obligated to indemnify any Innate Indemnified Party if and to the extent that the relevant Damages are directly or indirectly caused by or arise out of any Innate Responsible Party’s negligence, willful misconduct, breach of this Agreement, or breach of any Applicable Laws in connection with the Exploitation of Products by Innate Responsible Parties.

11.2 Indemnification by Innate

Innate shall indemnify, defend and hold harmless Sanofi, its Affiliates, and its and their respective officers, directors, employees, and agents, and their respective successors, heirs and assigns and representatives (individually and collectively, the “Sanofi Indemnified Parties”), from and against any and all Damages that are caused by (whether directly or indirectly):

11.2.1 any failure to timely perform any covenant, obligation or undertaking of Innate under this Agreement,

11.2.2 any representation or warranty set forth herein being untrue in any material respect when made by Innate, or

11.2.3 any breach or violation of any Law by any of Innate, its Affiliates, or subcontractors, or any of their respective officers, directors, sales representatives, employees, or agents (collectively, “Innate Responsible Parties”) in connection with the activities contemplated by this Agreement, including in the research, Development or Exploitation of Materials or Products pursuant hereto, or any negligent act or omission of any Innate Responsible Party in connection thereto.

61/147

The foregoing notwithstanding, Innate shall under no circumstances be obligated to indemnify any Sanofi Indemnified Party if and to the extent that the relevant Damages are directly or indirectly caused by or arise out of any Sanofi Responsible Party’s negligence, willful misconduct, breach of this Agreement, or breach of any Applicable Laws in connection with the Exploitation of Products by Sanofi Responsible Parties.

11.3 Indemnification Procedure

11.3.1 Promptly after receipt by a Party of notice, or such Party otherwise becoming aware, of any actual or potential claim by a Third Party which could give rise to a right to indemnification pursuant to Section 11.1 or Section 11.2 (each, a “Third Party Claim”), such Party shall promptly give the other Party written notice describing the Third Party Claim in reasonable detail. The indemnified Party shall not take any action that impairs the defense of any Third Party Claim by the indemnifying Party. The failure or delay of a Party to give notice in the manner provided herein shall not relieve the indemnifying Party of its obligations under this Article 11, except to the extent that such failure or delay to give notice materially prejudices the indemnifying Party’s ability to defend such Third Party Claim.

11.3.2 The indemnifying Party shall have the right, exercisable by written notice to the indemnified Party within |||||||||||||||||||||||||||||||||||| of receipt of notice of the commencement of or assertion of any Third Party Claim, to assume the defense of such Third Party Claim. Following such notice, the indemnifying Party shall, at its sole cost and expense, assume and conduct such defense, with counsel selected by the indemnifying Party and reasonably acceptable to the indemnified Party. However, if no such notice is given, or if the indemnified Party reasonably determines that the Third Party Claim is material to its business, then the indemnified Party shall be entitled to retain control of the defense of such Third Party Claim at its own expense.

11.3.3 If the indemnifying Party undertakes to defend any Third Party Claim as provided in Section 11.3.1 above, the indemnified Party agrees to reasonably cooperate with the indemnifying Party and its counsel in the defense of such Third Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or appeals as may reasonably be requested by the indemnifying Party. All reasonable costs and expenses incurred in connection with such cooperation shall be borne by the indemnifying Party. The indemnified Party shall have the right to participate in (but not control) and be represented by its own counsel (at the indemnified Party’s own expense) in connection with such Third Party Claim.

11.3.4 If the indemnifying Party does not defend the Third Party Claim, or fails to notify the indemnified Party of its election to defend as herein provided, the indemnified Party shall have the right, at its option, to defend such Third Party Claim by counsel of its choice and its reasonable costs and expenses for such Third Party Claim shall be included as part of the indemnification obligation of the indemnifying Party hereunder.

11.3.5 Notwithstanding the foregoing, neither Party may settle or compromise any Third Party Claim without the other Party’s prior written consent which would: (i) commit the other Party to take, or to forbear to take, any action; (ii) subject the other Party to an injunction; (iii) constitute an admission of guilt or liability by the other Party; or (iv) impose any financial liability on the other Party.

11.3.6 The Parties shall in all cases reasonably cooperate in the defense of any Third Party

62/147

Claims and each Party shall make reasonably available to the other Party any books, records or other documents within its control that are reasonably necessary or appropriate for such defense. Notwithstanding anything to the contrary in this Section 11.3, the Party conducting the defense of a Third Party Claim shall (i) keep the other Party informed on a reasonable and timely basis as to the status of the defense of such Third Party Claim, and (ii) conduct the defense of such Third Party Claim in a prudent manner.

11.4 Indemnification Payment Adjustments

The amount of any damages for which indemnification is provided under Section 11.1 or Section 11.2 shall be reduced by any insurance proceeds received or other amounts actually recovered, if any, by the indemnified Party with respect to such Damages; provided, however, that the indemnified Party shall not be subject to an obligation to pursue an insurance claim relating to any Damages for which indemnification is sought hereunder.

11.5 LIMITATION ON DAMAGES

IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, OR ANY DAMAGES CONSTITUTING LOST PROFITS UNDER THIS AGREEMENT OR ANY OTHER AGREEMENT OR INSTRUMENT CONTEMPLATED HEREBY, EXCEPT TO THE EXTENT OF ANY SUCH DAMAGES PAID TO A THIRD PARTY AS PART OF AN INDEMNIFICATION CLAIM HEREUNDER.

ARTICLE 12. TERM AND TERMINATION

12.1 Effectiveness; Term

The Agreement shall, without any further action by the Parties, automatically become effective as of the Effective Date. It shall thereafter continue in full force and effect from and after the Effective Date until the date on which all of Sanofi’s payment obligations under Article 7 have been performed or have expired, unless earlier terminated in accordance with the terms hereof or by mutual written agreement of the Parties (the “Term”).

12.2 Termination Rights

12.2.1 Insolvency

Either Party shall have the right to terminate this Agreement in such Party’s sole discretion, immediately upon delivery of a written notice to the other Party in the event that (i) such other Party becomes insolvent, (ii) a liquidation, bankruptcy or receivership proceeding under any applicable bankruptcy Law is commenced by such other Party, as a debtor, or if such other Party is served with an involuntary petition against it in any insolvency proceeding, upon the ninety-first (91st) calendar day after such service if such involuntary petition has not previously been stayed or dismissed, or (iii) upon the making by the other Party of an assignment of substantially all of its assets for the benefit of its creditors.

12.2.2 Termination for Material Breach

(a) Subject to Section 12.2.2(b) below, at any time during the Term, a Party shall have the right to terminate this Agreement, in such Party’s sole discretion, on

63/147

a Selected Target per Selected Target basis or on a Product-per-Product basis, by delivery of written notice to the other Party in the event of any uncured material breach by such other Party of this Agreement. Any such notice shall be in writing and shall specify the nature of the alleged material breach in reasonable detail and the breaching Party will then have a period of |||||||||||||||||||||||||||||||||||||||||||||||||||||| in which to cure the breach; provided, however, that, to the extent such material breach involves the failure to make a payment when properly due hereunder, such material breach must be cured within |||||||||||||||||||||||||||||||||||||||||||||||||||||| after written notice thereof. Notwithstanding the foregoing, if such material breach, by its nature, cannot be cured within the applicable cure period, then such cure period shall be extended if, prior to the end of the initial |||||||||||||||||||||||||||||||||||||||||||||||||||||| cure period, the non-terminating Party provides a reasonable written plan for curing such material breach and thereafter uses Commercially Reasonable Efforts to cure or alleviate such material breach in accordance with such written plan; provided that no such extension shall exceed an additional |||||||||||||||||||||||||||||||||||||||||||||||||||||| from the end of the initial |||||||||||||||||||||||||||||||||||||||||||||||||||||| cure period. A termination for breach will be effective upon the expiration of the cure period, as may be extended pursuant to this Section 12.2.2 (a).

(b) To the extent that the Parties are, at such time, researching, Developing or Commercializing two (2) or more Products, the non-breaching Party will have the right to determine whether to exercise this termination right on a Selected Target per Selected Target basis, or Product-by-Product basis, or for the entire Agreement. Any such determination will be clearly stated in the termination notice provided pursuant to Section 12.2.2 (a).

12.2.3 Termination for Convenience by Sanofi

Sanofi shall have the right, exercisable in its sole discretion, to terminate this Agreement in its entirety, on a Selected Target per Selected Target basis, or Product-per-Product basis (including the right for Sanofi to terminate the Exploitation of one Product among several Products Targeting the same Selected Target), for any reason (or without cause), at any time by providing the other Party with a ||||||||||||||||||||||||||||||||||||| prior written notice to that effect. Any such termination shall be effective upon expiration of such |||||||||||||||||||||||||||||||||||| notice period;

12.3 Consequences of Termination

12.3.1 Consequences of (i) a termination by Innate for Sanofi’s insolvency pursuant to Section 12.2.1, (ii) a termination by Innate for a material breach by Sanofi remained uncured pursuant to Section 12.2.2, or (iii) a termination by Sanofi for convenience pursuant to Section 12.2.3:

(a) Without prejudice to any other remedies, upon the termination of the Agreement by Innate in case of a material breach by Sanofi or Sanofi’s insolvency, or upon termination by Sanofi for convenience:

(i) any Research Program that is the subject of the termination will immediately cease unless in case of a Termination for Convenience by Sanofi pursuant to Section 12.2.3, Sanofi decides to terminate less than all Products which are Exploited by Sanofi under such Research Program, and subject to any applicable notice period;

64/147

(ii) all licenses and option rights granted by Innate to Sanofi and by Sanofi to Innate regarding the Multispecific Antibody or Product that is the subject of the termination (a “Discontinued Product”) will immediately terminate;

(iii) any sublicenses granted by Sanofi regarding the Discontinued Product will immediately terminate; and

(iv) the Non-Compete of Section 2.2.4 will immediately terminate on a Selected Target per Selected Target basis, and only upon termination of all Multispecific Antibodies and Products Targeting such Selected Target.

65/147

66/147

67/147

||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

68/147

12.3.2 Consequences of (i) a termination by Sanofi for Innate’s insolvency pursuant to Section 12.2.1or (ii) a termination by Sanofi for a material breach by Innate pursuant to Section 12.2.2:

Upon the termination of the Agreement by Sanofi for a material breach of this Agreement by Innate or for Innate’s insolvency, without prejudice to any other remedies:

(a) Any Research Program that is the subject of the termination will immediately cease;

(b) All licenses granted to Innate by Sanofi pursuant to this Agreement will immediately terminate;

69/147

(d) All licenses granted to Sanofi by Innate will become perpetual and irrevocable, and Sanofi may therefore continue to research, Develop, Manufacture and Commercialize Multispecific Antibodies Targeting a Selected Target and Products throughout the Territory, subject to the financial provisions of Article 7 as adjusted pursuant to subclause (f);

(e) All option rights shall terminate provided that Sanofi will be entitled to exercise its Option rights with respect to a Pre-Selected Target or a New Target and Innate shall grant a perpetual and irrevocable license with respect to such Selected Targets, and Sanofi may therefore continue to research, Develop, Manufacture and Commercialize Multispecific Antibodies Targeting a Selected Target and Products throughout the Territory, subject to the financial provisions of Article 7 as adjusted pursuant to subclause (f).

(f) Notwithstanding the foregoing, in the case of a perpetual license pursuant to paragraphs (d) and (e) above:

(i) all applicable payments to be made by Sanofi to Innate pursuant to Article 7 during the remaining Term shall be reduced by |||||||||; and

(ii) The Parties shall use Commercially Reasonable Efforts to (A) transfer to Sanofi, within 90 days of the receipt of the Termination Notice by Innate, all on-going Innate’s activities and all Collaboration Materials and (B) to deliver and assign to Sanofi all data, results, regulatory information and any files in the possession of Innate as of the effective date of such termination included in any regulatory filing, Regulatory Approval, drug master file, by Innate or its Affiliates or Sublicensees and that relate to any terminated Research Program, and Innate shall provide to Sanofi all reasonable assistance in connection with such transfer.

12.3.3 Additional Consequences of (i) a termination by either Party for other Party’s insolvency pursuant to Section 12.2.1, (ii) a termination by either Party for a material breach by the other Party pursuant to Section 12.2.2, or (iii) a termination by Sanofi for convenience pursuant to Section 12.2.3.

Within |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| after the effective date of termination:

70/147

12.3.4 Surviving Provisions

If this Agreement is terminated as provided in Article 12, the provisions of this Agreement shall terminate other than those which according to their nature or their terms shall survive termination, including the following provisions in accordance with the terms thereof: Sections 1 (Definition); Sections 7.3-7.7 (with respect to payments accruing prior to but not yet paid as of, the effective date of termination); Section 7.7; Section 7.9 (Payment Terms); Section 8.1 (Intellectual Property Ownership); Section 8.2 and Section 8.3 (with respect to Collaboration Patents and with respect to any enforcement actions being prosecuted as of the effective date of termination); Article 10 (Confidentiality); Article 11 (Indemnification); Section 12.3 (Consequences of termination); Article 14 (Miscellaneous, including the choice of law and jurisdiction); (ii) such termination shall not relieve either Party of any obligation, or deprive either Party from any benefit, accruing prior thereto, and (iii) such termination shall be without prejudice to the rights and remedies of any Party with respect to any antecedent breach of the provisions of this Agreement.

ARTICLE 13. GOVERNMENT APPROVALS

13.1 Efforts.

Each of Innate and Sanofi will use its Commercially Reasonable Efforts to remove promptly any and all impediments to consummation of the Contemplated Transactions, including obtaining government antitrust clearance, cooperating in good faith with any governmental authority investigation, promptly producing any documents and information and providing witness testimony if requested by a governmental authority. Notwithstanding anything to the contrary in this Agreement, this Section 13.1 and the term “commercially reasonable good faith efforts” do not require that either Party (i) offer, negotiate, commit to or effect, by consent decree, hold separate order, trust or otherwise, the sale, divestiture, license or other disposition of any capital stock, assets, rights, products or businesses of Innate or Sanofi or their respective Affiliates, (ii) agree to any restrictions on the businesses of Innate or Sanofi or their respective Affiliates, or (iii) pay any amount or take any other action to prevent, effect

71/147

the dissolution of, vacate, or lift any decree, order, judgment, injunction, temporary restraining order, or other order in any suit or proceeding that would otherwise have the effect of preventing or delaying the Contemplated Transactions (collectively, an “Antitrust Remedy”).

13.2 Filings.

As soon as reasonably practicable following the Execution Date (but no later than ten (10) Business Days following the Execution Date unless otherwise agreed to in writing by the Parties), each of Innate and Sanofi will prepare and submit to the United States Federal Trade Commission (the “FTC”), the Antitrust Division of the United States Department of Justice (the “DOJ”) any HSR/Antitrust Filing required of it under the HSR Act, along with a request for “early termination” of the applicable HSR waiting period, and, as soon as practicable, file with the appropriate governmental authority any other HSR/Antitrust Filing required of it under any other Antitrust Law as determined in the reasonable opinion of either Party with respect to the Contemplated Transactions. The Parties shall cooperate with one another to the extent necessary in the preparation of any such HSR/Antitrust Filing. Each Party shall be responsible for its own external legal and internal costs and expenses associated with any HSR/Antitrust Filing; provided, however, that Sanofi shall pay all fees (other than penalties that may be incurred as a result of actions or omissions on the part of a Party, which penalties shall be the sole financial responsibility of such Party) required to be paid to any governmental authority in connection with making any such HSR/Antitrust Filing. In the event that the Parties make an HSR/Antitrust Filing under this Section 13.2, this Agreement shall terminate (i) at the election of either Party, immediately upon notice to the other Party, in the event that the FTC, DOJ or other governmental authority (x) obtains a preliminary injunction or final order under Antitrust Law enjoining the Contemplated Transactions, or (y) issues an Antitrust Remedy as a condition of approval, or (ii) at the election of either Party, immediately upon notice to the other Party, upon the occurrence of the Outside Date. Notwithstanding anything to the contrary contained herein, except for the terms and conditions of this Article 13, none of the terms and conditions contained in this Agreement shall be effective until the “Effective Date,” which is agreed and understood to mean, subject to the Closing Conditions having been fulfilled or waived in accordance with Section 0 (Closing Conditions), the later of (A) if a determination is made pursuant to this Section 13.2 that an HSR/Antitrust Filing is not required to be made under any Antitrust Law for this Agreement, the date of such determination, or (B) if a determination is made pursuant to this Section 13.2 that an HSR/Antitrust Filing is required to be made under any Antitrust Law for this Agreement, the Antitrust Clearance Date. As used herein: (1) “Antitrust Clearance Date” means the earliest date on which the Parties have actual knowledge that all applicable waiting periods under the HSR Act and any comparable waiting periods as required under any other Antitrust Law, in each case with respect to the Contemplated Transactions have expired or have been terminated; and (2) “HSR/Antitrust Filing” means (x) a filing by Innate and a filing by Sanofi with the FTC and the DOJ of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act), together with all required documentary attachments thereto or (y) any comparable filing by Innate or Sanofi required under any other Antitrust Law, in each case ((x) and (y)) with respect to the Contemplated Transactions.

13.3 Information Exchange.

Each of Innate and Sanofi will, in connection with any HSR/Antitrust Filing, (a) reasonably cooperate with each other in connection with any communication, filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private party; (b) keep the other Party and/or its counsel informed of any communication received by such Party from, or given by such Party to, the FTC, the DOJ or any other U.S. or other Governmental Authority and of any communication received or given in connection with any proceeding by a private party, in each case regarding the transaction contemplated by this Agreement; (c) consult with each other in advance of any meeting or conference with the FTC, the DOJ or any other governmental authority or, in connection with any proceeding by a private party, with any other Person, and to the extent permitted by the FTC, the DOJ or such other governmental authority or other Person, give the Parties and/or their counsel the opportunity to attend and participate in such meetings and conferences; and (d) to the extent practicable,

72/147

permit the other Party and/or its counsel to review in advance any submission, filing or communication (and documents submitted therewith) intended to be given by it to the FTC, the DOJ or any other governmental authority; provided, that materials may be redacted to remove references concerning the valuation of the business of the disclosing Party or other sensitive information in the judgment of such disclosing Party. Innate and Sanofi, as each deems advisable and necessary, may reasonably designate any competitively sensitive material to be provided to the other under this Article 13 as “Antitrust Counsel Only Material.” Such materials and the information contained therein shall be given only to the outside antitrust counsel of the recipient and will not be disclosed by such outside counsel to employees, officers or directors of the recipient unless express permission is obtained in advance from the source of the materials (Innate or Sanofi, as the case may be) or its legal counsel.

ARTICLE 14. MISCELLANEOUS

14.1 Severability

If and to the extent that any provision (or any part thereof) of this Agreement is held to be invalid, illegal or unenforceable, in any respect in any jurisdiction, the provision shall be considered severed from this Agreement and shall not serve to invalidate the remainder of such provision or any other provisions hereof. The Parties shall make a good faith effort to replace any invalid, illegal or unenforceable provision (or any part thereof) with a valid, legal and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.

14.2 Notices

Any notice required or permitted to be given by the Parties pursuant to this Agreement shall be in writing and shall be (i) delivered by hand or overnight courier with tracking capabilities, or (ii) mailed postage prepaid by first class, registered or certified mail, or (iii) transmitted by facsimile, with confirmation copy by mail as provided in (ii), and in each case addressed to the recipient Party as set forth below, unless changed by notice so given:

If to Sanofi:

Sanofi

46, avenue de la Grande Armée

750017 Paris

France

Attention: Legal Department – Alliance Management

With a copy (which shall not constitute notice) to the Sanofi Alliance Manager at alliance.management@sanofi.com

If to Innate:

Innate Pharma

117 avenue de Luminy

BP 30191

13276 Marseille cedex 09

France

Attention: General Counsel

Any such notice shall be deemed effective as of, as applicable (i) when delivered if delivered by hand, by courier or by facsimile (or on the next Business Day if delivered on a non-Business Day), or (ii) on the fifth (5th) Business Day following the date of mailing, if sent by mail. A Party may add, delete, or

73/147

change the address to which notices should be sent at any time upon written notice delivered to the other Party in accordance with this Section 14.2.

14.3 Force Majeure

Neither Party shall be liable for delay or failure in the performance of any of its obligations hereunder to the extent such delay or failure is due to causes beyond its reasonable control, including, without limitation, acts of God, fires, floods, earthquakes, epidemics, disease, strikes and labor disputes, acts of war, terrorism, civil unrest or intervention of any governmental authority. The affected Party shall promptly notify the other Party and shall use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and shall continue performance as soon as such causes are removed.

14.4 Assignment

Neither this Agreement nor any of the rights or obligations hereunder may be assigned or transferred by either Party without the prior written consent of the other Party, such consent not to be unreasonably withheld or delayed; provided, however, that either Party may, without the other Party’s consent, assign or transfer this Agreement and all of its rights and obligations hereunder to (a) any Affiliate (provided further that such interest shall be transferred back to the assigning Party if such entity ceases to be an Affiliate of the assigning Party) or (b) in connection with a merger, consolidation or sale of substantially all of the business to which this Agreement relates to a Third Party. The assigning Party shall in any event remain responsible for and liable hereunder with respect to the acts and omissions of its Affiliate in the performance of this Agreement. This Agreement shall inure to the benefit of and be binding on the Parties’ successors and assigns. Any assignment or transfer in violation of the foregoing shall be null and void and wholly invalid, the assignee or transferee in any such assignment or transfer shall acquire no rights whatsoever, and the non-assigning non-transferring Party shall not recognize, nor shall it be required to recognize, such assignment or transfer.

14.5 Further Assurances

Each Party agrees, at its own expense, to do, or procure the doing of, all such further acts and things and shall execute and deliver such other agreements, certificates, instruments and documents as are reasonably necessary in order to give full effect to this Agreement.

14.6 Waivers and Modifications

No waiver, modification, release or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by all Parties hereto. The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of such obligation. Waiver of any provision hereunder or of any breach of any provision hereof shall not be deemed to be a continuing waiver or a waiver of any other breach of such provision (or any other provision) on such occasion or any succeeding occasion.

14.7 Choice of Law

This Agreement (and any claims or disputes arising out of or relating hereto or to the transactions contemplated hereby or to the inducement of any Party to enter herein or therein, whether for breach of

74/147

contract, tortious conduct or otherwise and whether predicated on common law, statute or otherwise) shall be governed by, enforced, and shall be construed in accordance with the laws of France, without regard to its conflicts of law provisions.

14.8 Jurisdiction

The competent courts located in Paris shall have exclusive jurisdiction to settle (a) any dispute arising out of or in connection with this Agreement (including a dispute relating to the existence, validity or termination of this Agreement) and (b) any dispute relating to any non-contractual obligation arising out or in connection with this Agreement.

14.9 Publicity

Following the execution of this Agreement, the Parties shall issue a press release announcing the existence of this Agreement in the form attached hereto as Schedule 14.9. Each Party agrees not to issue any other press release or other public statement disclosing other information relating to this Agreement or the transactions contemplated hereby without the prior written consent of the other Party, other than pursuant to Section 10.4.

14.10 Relationship of the Parties

Each Party is an independent contractor under this Agreement. Nothing herein is intended or is to be construed so as to constitute Innate and Sanofi as partners, agents or joint venturers. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party. There are no express or implied Third Party beneficiaries hereunder.

14.11 Entire Agreement

This Agreement and the attached Schedules and Exhibits constitutes the entire agreement between the Parties as to the subject matter of this Agreement, and hereby supersedes all prior negotiations, representations, agreements and understandings (whether written or verbal) regarding the same.

14.12 Counterparts

This Agreement may be executed in two or more counterparts, or by other electronic signatures, with the same effect as if both Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall together constitute one and the same instrument.

14.13 Amendments

Any amendment of this Agreement shall not be binding on the Parties unless set out in writing, expressed to amend this Agreement and signed by authorized representatives of each of the Parties.

14.14 No presumption against the drafters

75/147

Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party hereto as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.

Innate Pharma S.A

Genzyme Corporation

/s/Mondher Mahjoubi

/s/Thaminda Ramanayake

MAHJoubi Mondher (16 déc. 2022 22:11 GMT+1)

Mondher MAHJOUBI, CEO

Thaminda RAMANAYAKE, Global Head of BD, Oncology

76/147

SCHEDULE 3.1.1(a)

77/147

78/147

79/147

80/147

81/147

82/147

83/147

84/147

85/147

86/147

87/147

88/147

89/147

90/147

91/147

92/147

93/147

94/147

95/147

96/147

97/147

98/147

99/147

SCHEDULE 3.1.1(b)

100/147

SCHEDULE 4.1

OPTION DATA PACKAGE

101/147

102/147

103/147

104/147

105/147

SCHEDULE 4.3

106/147

107/147

LIST OF ABBREVIATIONS

108/147

109/147

110/147

|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

111/147

112/147

113/147

114/147

115/147

116/147

117/147

118/147

119/147

120/147

121/147

122/147

123/147

124/147

125/147

126/147

127/147

128/147

129/147

130/147

131/147

132/147

133/147

134/147

SCHEDULE 4.10

SANOFI POLICY ON ANIMAL PROTECTION

135/147

136/147

SCHEDULE 7.7

137/147

138/147

139/147

140/147

SCHEDULE 14.9

DRAFT PRESS RELEASES

INNATE PRESS RELEASE

SANOFI AND INNATE PHARMA EXPAND COLLABORATION FOR

NATURAL KILLER CELL THERAPEUTICS IN ONCOLOGY

• Sanofi gains exclusive license to Innate's B7H3 ANKET™ program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all research, development, manufacturing and commercialization

• Innate to receive €25m upfront and up to €1.35bn in total milestones plus royalties from Sanofi


Marseille, France, XX, 2022, 7:00 AM CET

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3from Innate's ANKET™ (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option on up to two additional ANKET™ targets. Upon candidate selection, Sanofi will be responsible for all research, development, manufacturing and commercialization.

Innate and Sanofi signed a first NK cell engagers collaboration in 2016 for the generation and evaluation of up to two bispecific NK cell engagers, which are currently being evaluated by Sanofi's R&D team.

Valeria Fantin, Ph.D., Global Head of Oncology Research at Sanofi

"At Sanofi, we are exploring the potential of NK cells for cancer immunotherapy, a key pillar for our oncology strategy. The expansion of the collaboration with Innate supports our ambition to develop a diverse portfolio of next-generation NK cell engagers, highly synergistic with Sanofi's allogeneic NK cell platform, engineered lymphokines that stimulate NK cells, and growing Immuno-oncology pipeline."

Yannis Morel, Ph.D., Executive Vice President, Product portfolio strategy & Business development at Innate Pharma

"Building on the success of our existing collaboration on hematologic targets, we are pleased to expand and strengthen our partnership with Sanofi on NK Cell Engagers with the addition of up to three new programs, including in solid tumors. Sanofi's investment in Innate further validates the value of our ANKET™ platform and its potential to address multiple tumor types. By incorporating various tumor antigen binders, NK Cell Engagers are a versatile technology that may provide new options for patients and offer clinical benefit across multiple cancers, whilst also maintaining a good safety profile. This agreement also highlights Innate's strategy to build a brood portfolio of ANKET programs addressing different types of cancer."

Under the terms of the new license agreement, Innate will receive €25m upfront payment and up to €1.35bn total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales. Closing of the transaction is subject to HSR approval.

141/147

About ANKETTM

ANKETTM (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.

This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. It leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells.

Our latest innovation, the tetra-specific ANKET molecule, is the first NK cell engager technology to engage activating receptors (NKp46 and CD16), a tumor antigen and an interleukin-2 receptor (via an IL-2 variant, IL-2v) via a single molecule.

About 2016 Sanofi/Innate research collaboration and licensing agreement

In 2016, Sanofi and Innate entered into a research collaboration and licensing agreement for the generation and evaluation of up to two bispecific NK cell engagers, using technology from Innate Pharma and Sanofi's proprietary bispecific antibody format as well as tumor targets.

A Phase 1/2 clinical trial by Sanofi is ongoing, evaluating IPH6101/SAR'579 (SAR443579), the first NKp46/CD16-based CD123-targeted ANKETTM NK cell engager, in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplastic syndrome (HR-MDS).

In the summer 2022, Sanofi had made the decision to progress IPH6401/SAR'514 (SAR445514) into investigational new drug (IND)-enabling studies. IPH6401/SAR'514 is a BCMA-targeting NK cell engager using Sanofi's proprietary CROSSODILE® multi -functional platform, which comprises the Cross-OverDual-Variable-Domain (CODV) format. It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on Innate's ANKETTM proprietary platform.

Under the terms of the original license agreement, Sanofi is responsible for the development, manufacturing and commercialization of products resulting from the research collaboration. Innate Pharma will be eligible to up to €400m in development and commercial milestone payments as well as royalties on net sales. To date, €13m milestone payments to Innate have been announced.

About Sanofi's approach to NK therapies in oncology

At Sanofi, we are exploring the intrinsic abilities of Natural Killer cells to create new immunotherapies for patients with cancer. Natural Killer cell-based therapies are a key pillar within Sanofi's Oncology strategy. By activating the innate power of NK cells, Sanofi is advancing a diverse and complementary range of NK-based therapeutics to transform immune biology. The breadth of our modalities and unique strength to innovate end-to-end maximizes the therapeutic possibilities for more people with cancer.

142/147

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma's broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multiproducts collaboration with AstraZeneca.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:


ISIN code			FR0010331421
Ticker code			Euronext: IPH Nasdaq: IPHA
LEI			9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts, the Company's continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company's business, financial

143/147

condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma

Media Relations

Arthur Rouille | +33 1 44 71 00 15 | innate@newcap.eu

Investors Relations

Henry Wheeler | +33 (0)4 84 90 32 88 | henry.wheeler@innate-pharma.fr

Sanofi

Media Relations

Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com

Sally Bain | + 1 617 834 6026 | sally.bain@sanofi.com

Kate Conway | + 1 508 364 4931 | kate.conway@sanofi.com

Investor Relations

Eva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com

Arnaud Delepine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com

Corentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.com

Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com

Priya Nanduri | +1 617 764 6418 | priya.nanduri@sanofi.com

Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

144/147

SANOFI DRAFT PRESS RELEASE

Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

Paris, December XX, 2022 Sanofi (NASDAQ: SNY) and Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced today an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate's ANKET™ (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option on up to two additional ANKET™ targets. Upon candidate selection, Sanofi will be responsible for all research, development, manufacturing and commercialization. Innate and Sanofi signed a first NK cell engagers collaboration in 2016 for the generation and evaluation of up to two bispecific NK cell engagers, which are currently being evaluated by Sanofi's R&D team.

Valeria Fantin, Ph.D.

Global Head of Oncology Research at Sanofi

“At Sanofi, we are exploring the potential ofNK cells for cancer immunotherapy, a key pillar for our oncology strategy. The expansion of the collaboration with Innate supports our ambition to develop a diverse portfolio of next-generation NK cell engagers, highly synergistic with Sanofi’s allogeneic NK cell platform, engineered lymphokines that stimulate NKcells, and growing Immuno-oncology pipeline.”

Yannis Morel, Ph.D.

Executive Vice President, Product portfolio strategy & Business development at Innate Pharma

“Building on the success of our existing collaboration on hematologic targets, ive are pleased to expand and strengthen our partnership with Sanofi onNK Cell Engagers with the addition of up to three new programs, including in solid tumors. Sanofi’s investment in Innate further validate the value of our ANKET™ platform and its potential to address multiple tumor types. By incorporating various tumor antigen binders, NK Cell Engagers are a versatile technology that may provide new options for patients and offer clinical benefit across multiple cancers, whilst also maintaining a good safety profile. This agreement also highlights Innate’s strategy to build a broad portfolio of ANKET programs addressing different types of cancer.”

About 2016 Sanofi/Innate research collaboration and licensing agreement

In 2016, Sanofi and Innate entered into a research collaboration and licensing agreement for the generation and evaluation of up to two bispecific NK cell engagers, using technology from Innate

145/147

Pharma and Sanofi's proprietary bispecific antibody format as well as tumor targets.

A Phase 1/2 clinical trial by Sanofi is ongoing, evaluating IPH6101/SAR'579 (SAR443579), the first NKp46/CD16-based CD123-targeted ANKET™ NK cell engager, in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplastic syndrome (HR-MDS).

In the summer 2022, Sanofi had made the decision to progress IPH6401/SAR'514 (SAR445514) into investigational new drug (IND)-enabling studies. IPH6401/SAR'514 is a BCMA-targeting NK cell engager using Sanofi's proprietary CROSSODILE® multi-functional platform, which comprises the Cross-Over- Dual-Variable-Domain (CODV) format. It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on Innate's ANKET™ proprietary platform.

About Sanofi's approach to NK therapies in oncology

About Sanofi

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

About Innate Pharma

Innate Pharma's broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

146/147

biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Sanofi

Media Relations

Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com

Sally Bain | + 1 617 834 6026 | sally.bain@sanofi.com

Kate Conway | + 1 508 364 4931 | kate.conway@sanofi.com

Investor Relations

Eva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com

Arnaud Delepine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com

Corentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.com

Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com

Priya Nanduri | +1 617 764 6418 | priya.nanduri@sanofi.com

Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

Innate Pharma

Media - Arthur Rouille | +33 1 44 71 00 15 | innate@newcap.eu

Investors - Henry Wheeler | +33 (0)4 84 90 32 88 | henry.wheeler@innate-pharma.fr

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

147/147


\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|			\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|

Innate Pharma (IPHA) 20-F/A2022 FY Annual report (foreign) (amended)